0001062822-20-000067.txt : 20201030 0001062822-20-000067.hdr.sgml : 20201030 20201030163521 ACCESSION NUMBER: 0001062822-20-000067 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201030 DATE AS OF CHANGE: 20201030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 201277822 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 10-Q 1 lxrx-20200930.htm 10-Q lxrx-20200930
Q3FALSE2020--12-31000106282200010628222020-01-012020-09-30xbrli:shares00010628222020-10-26iso4217:USD00010628222020-09-3000010628222019-12-3100010628222019-09-30iso4217:USDxbrli:shares00010628222020-07-012020-09-3000010628222019-07-012019-09-3000010628222019-01-012019-09-3000010628222020-04-012020-06-300001062822us-gaap:CommonStockMember2018-12-310001062822us-gaap:AdditionalPaidInCapitalMember2018-12-310001062822us-gaap:RetainedEarningsMember2018-12-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001062822us-gaap:TreasuryStockMember2018-12-3100010628222018-12-310001062822us-gaap:CommonStockMember2019-01-012019-03-310001062822us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001062822us-gaap:RetainedEarningsMember2019-01-012019-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001062822us-gaap:TreasuryStockMember2019-01-012019-03-3100010628222019-01-012019-03-310001062822us-gaap:CommonStockMember2019-03-310001062822us-gaap:AdditionalPaidInCapitalMember2019-03-310001062822us-gaap:RetainedEarningsMember2019-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001062822us-gaap:TreasuryStockMember2019-03-3100010628222019-03-310001062822us-gaap:CommonStockMember2019-04-012019-06-300001062822us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001062822us-gaap:RetainedEarningsMember2019-04-012019-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001062822us-gaap:TreasuryStockMember2019-04-012019-06-3000010628222019-04-012019-06-300001062822us-gaap:CommonStockMember2019-06-300001062822us-gaap:AdditionalPaidInCapitalMember2019-06-300001062822us-gaap:RetainedEarningsMember2019-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001062822us-gaap:TreasuryStockMember2019-06-3000010628222019-06-300001062822us-gaap:CommonStockMember2019-07-012019-09-300001062822us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001062822us-gaap:RetainedEarningsMember2019-07-012019-09-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001062822us-gaap:TreasuryStockMember2019-07-012019-09-300001062822us-gaap:CommonStockMember2019-09-300001062822us-gaap:AdditionalPaidInCapitalMember2019-09-300001062822us-gaap:RetainedEarningsMember2019-09-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001062822us-gaap:TreasuryStockMember2019-09-300001062822us-gaap:CommonStockMember2019-12-310001062822us-gaap:AdditionalPaidInCapitalMember2019-12-310001062822us-gaap:RetainedEarningsMember2019-12-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001062822us-gaap:TreasuryStockMember2019-12-310001062822us-gaap:CommonStockMember2020-01-012020-03-310001062822us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001062822us-gaap:RetainedEarningsMember2020-01-012020-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001062822us-gaap:TreasuryStockMember2020-01-012020-03-3100010628222020-01-012020-03-310001062822us-gaap:CommonStockMember2020-03-310001062822us-gaap:AdditionalPaidInCapitalMember2020-03-310001062822us-gaap:RetainedEarningsMember2020-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001062822us-gaap:TreasuryStockMember2020-03-3100010628222020-03-310001062822us-gaap:CommonStockMember2020-04-012020-06-300001062822us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001062822us-gaap:RetainedEarningsMember2020-04-012020-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001062822us-gaap:TreasuryStockMember2020-04-012020-06-300001062822us-gaap:CommonStockMember2020-06-300001062822us-gaap:AdditionalPaidInCapitalMember2020-06-300001062822us-gaap:RetainedEarningsMember2020-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001062822us-gaap:TreasuryStockMember2020-06-3000010628222020-06-300001062822us-gaap:CommonStockMember2020-07-012020-09-300001062822us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001062822us-gaap:RetainedEarningsMember2020-07-012020-09-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001062822us-gaap:TreasuryStockMember2020-07-012020-09-300001062822us-gaap:CommonStockMember2020-09-300001062822us-gaap:AdditionalPaidInCapitalMember2020-09-300001062822us-gaap:RetainedEarningsMember2020-09-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001062822us-gaap:TreasuryStockMember2020-09-3000010628222020-09-012020-09-3000010628222020-09-0800010628222017-03-31xbrli:pure0001062822us-gaap:StockOptionMember2020-01-012020-09-300001062822us-gaap:StockOptionMember2019-01-012019-09-300001062822us-gaap:EmployeeStockOptionMember2019-12-310001062822us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001062822us-gaap:EmployeeStockOptionMember2020-09-300001062822us-gaap:RestrictedStockUnitsRSUMember2019-12-310001062822us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001062822us-gaap:RestrictedStockUnitsRSUMember2020-09-300001062822srt:ScenarioForecastMember2020-01-012020-12-310001062822lxrx:RDSeveranceCostsMember2020-01-012020-09-300001062822lxrx:SGASeveranceCostsMember2020-01-012020-09-300001062822us-gaap:CashMember2020-09-300001062822us-gaap:USTreasurySecuritiesMember2020-09-300001062822us-gaap:CorporateDebtSecuritiesMember2020-09-300001062822us-gaap:CorporateDebtSecuritiesMember2019-09-300001062822us-gaap:ShortTermInvestmentsMember2020-09-300001062822us-gaap:InvestmentsMember2020-09-300001062822us-gaap:CashMember2019-12-310001062822us-gaap:USTreasurySecuritiesMember2019-12-310001062822us-gaap:ShortTermInvestmentsMember2019-12-310001062822us-gaap:InvestmentsMember2019-12-310001062822us-gaap:FairValueInputsLevel1Member2020-09-300001062822us-gaap:FairValueInputsLevel2Member2020-09-300001062822us-gaap:FairValueInputsLevel3Member2020-09-300001062822us-gaap:FairValueInputsLevel1Member2019-12-310001062822us-gaap:FairValueInputsLevel2Member2019-12-310001062822us-gaap:FairValueInputsLevel3Member2019-12-3100010628222014-11-012014-11-3000010628222014-11-2000010628222020-09-280001062822us-gaap:SubsequentEventMember2020-10-0100010628222018-08-3000010628222017-12-180001062822lxrx:BioPharmaMember2020-01-012020-09-300001062822us-gaap:AccountsReceivableMember2020-01-012020-09-3000010628222015-03-012015-03-3100010628222017-01-012017-03-3100010628222018-01-012018-03-3100010628222017-10-012017-10-3100010628222017-11-012017-11-3000010628222019-10-012019-12-3100010628222019-02-012019-02-28iso4217:EUR00010628222014-10-012014-10-3100010628222015-01-012015-12-3100010628222016-01-012016-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 (Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2020
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from _____________ to _____________
Commission File Number:  000-30111
Lexicon Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware76-0474169
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
Identification Number)
8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of Principal Executive Offices and Zip Code)
(281) 863-3000
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001LXRXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes☑ No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes☑ No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer              Accelerated filer  ☑       Non-accelerated filer          
Smaller reporting company    ☐       Emerging growth company  ☐        
If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes☐ No☑

As of October 26, 2020, 117,474,808 shares of the registrant’s common stock, par value $0.001 per share, were outstanding. ☐


Lexicon Pharmaceuticals, Inc.
 
Table of Contents
 
  Page
Item 1.
 Condensed Consolidated Balance Sheets - September 30, 2020 (unaudited) and December 31, 2019
 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - Three and Nine Months Ended September 30, 2020 and 2019
 Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited) - Three and Nine Months Ended September 30, 2020 and 2019
Condensed Consolidated Statements of Cash Flows (unaudited) - Nine Months Ended September 30, 2020 and 2019
 Notes to Condensed Consolidated Financial Statements (unaudited)
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 6.

The Lexicon name and logo are registered trademarks and Zynquista™ is a trademark of Lexicon Pharmaceuticals, Inc.
 
——————

Factors Affecting Forward Looking Statements
This quarterly report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Part II, Item 1A. - Risk Factors” and in our annual report on Form 10-K for the year ended December 31, 2019, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.


2

Part I – Financial Information
 
Item 1.  Financial Statements
 
Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets
(In thousands, except par value)
 
 As of September 30,As of December 31,
 20202019
Assets(unaudited) 
Current assets:  
Cash and cash equivalents$52,251 $36,112 
Short-term investments59,195 235,547 
Accounts receivable, net1,383 56,532 
Inventory— 4,243 
Prepaid expenses and other current assets9,109 5,320 
Total current assets121,938 337,754 
Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively
11,106 14,047 
Goodwill44,543 44,543 
Intangible assets, net — 19,716 
Other assets1,341 1,655 
Total assets$178,928 $417,715 
Liabilities and Equity  
Current liabilities:  
Accounts payable$11,734 $12,178 
Accrued liabilities58,497 42,151 
Current portion of long-term debt, net of deferred issuance costs8,691 11,012 
Total current liabilities78,922 65,341 
Long-term debt, net of deferred issuance costs11,629 234,171 
Other long-term liabilities738 1,102 
Total liabilities91,289 300,614 
Commitments and contingencies
Stockholders’ Equity:  
Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding
— — 
Common stock, $0.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively
117 106 
Additional paid-in capital1,486,853 1,462,172 
Accumulated deficit(1,394,523)(1,341,444)
Accumulated other comprehensive income35 84 
Treasury stock, at cost, 793 and 407 shares, respectively
(4,843)(3,817)
Total stockholders’ equity87,639 117,101 
Total liabilities and equity$178,928 $417,715 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

3

Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)
(In thousands, except per share amounts)
(Unaudited)
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Revenues:  
Net product revenue$6,542 $8,351 $23,404 $23,763 
Collaborative agreements— 285,910 33 289,209 
Royalties and other revenue92 187 359 374 
Total revenues6,634 294,448 23,796 313,346 
Operating expenses:  
Cost of sales (including finite-lived intangible asset amortization)
633 577 1,929 2,457 
Research and development, including stock-based compensation of $1,029, $1,698, $5,154 and $5,369, respectively
40,147 26,659 152,629 51,318 
Selling, general and administrative, including stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively
11,997 13,898 40,798 42,271 
Impairment loss on buildings
— — 1,600 — 
Impairment loss on intangible asset— 28,638 — 28,638 
Total operating expenses52,777 69,772 196,956 124,684 
Other operating income:
Gain on sale of XERMELO132,818 — 132,818 — 
Income (loss) from operations86,675 224,676 (40,342)188,662 
Loss on debt extinguishments, net(255)— (255)— 
Interest expense (4,118)(5,204)(14,374)(15,485)
Interest and other income, net301 600 1,892 2,080 
Net income (loss) before taxes82,603 220,072 (53,079)175,257 
Income tax benefit— 6,014 — 6,014 
Net income (loss)$82,603 $226,086 $(53,079)$181,271 
Net income (loss) per common share, basic $0.77 $2.13 $(0.50)$1.71 
Net income (loss) per common share, diluted$0.71 $1.95 $(0.50)$1.59 
Shares used in computing net income (loss) per common share, basic 107,309 106,272 106,974 106,200 
Shares used in computing net income (loss) per common share, diluted  117,552 116,640 106,974 116,742 
Other comprehensive income (loss):
Unrealized gain (loss) on investments
(277)(50)(49)48 
Comprehensive income (loss)$82,326 $226,036 $(53,128)$181,319 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Lexicon Pharmaceuticals, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands)
(Unaudited)

Common StockAdditionalAccumulated Other
SharesPar ValuePaid-In CapitalAccumulated DeficitComprehensive Gain (Loss)Treasury StockTotal
Balance at December 31, 2018106,162 $106 $1,447,954 $(1,471,577)$(12)$(2,876)$(26,405)
Stock-based compensation— — 3,411 — — — 3,411 
Issuance of common stock under Equity Incentive Plans517 — — — — — — 
Repurchase of common stock— — — — — (941)(941)
Net loss— — — (21,797)— — (21,797)
Unrealized gain on investments— — — — 45 — 45 
Balance at March 31, 2019106,679 106 1,451,365 (1,493,374)33 (3,817)(45,687)
Stock-based compensation— — 3,766 — — — 3,766 
Net loss— — — (23,018)— — (23,018)
Unrealized gain on investments— — — — 53 — 53 
Balance at June 30, 2019106,679 106 1,455,131 (1,516,392)86 (3,817)(64,886)
Stock-based compensation— — 3,562 — — — 3,562 
Net income— — — 226,086 — — 226,086 
Unrealized loss on investments— — — — (50)— (50)
Balance at September 30, 2019106,679 $106 $1,458,693 $(1,290,306)$36 $(3,817)$164,712 
















5


Lexicon Pharmaceuticals, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands)
(Unaudited)

Common StockAdditionalAccumulated Other
SharesPar ValuePaid-In CapitalAccumulated DeficitComprehensive Gain (Loss)Treasury StockTotal
Balance at December 31, 2019106,679 $106 $1,462,172 $(1,341,444)$84 $(3,817)$117,101 
Stock-based compensation— — 4,432 — — — 4,432 
Issuance of common stock under Equity Incentive Plans1,032 2 — — — — 2 
Repurchase of common stock— — — — — (923)(923)
Net loss— — — (66,611)— — (66,611)
Unrealized gain on investments— — — — 776 — 776 
Balance at March 31, 2020107,711 108 1,466,604 (1,408,055)860 (4,740)54,777 
Stock-based compensation— — 4,258 — — — 4,258 
Issuance of common stock under Equity Incentive Plans187 — — — — — — 
Repurchase of common stock— — — — — (103)(103)
Net loss— — — (69,071)— — (69,071)
Unrealized loss on investments— — — — (548)— (548)
Balance at June 30, 2020107,898 108 1,470,862 (1,477,126)312 (4,843)(10,687)
Stock-based compensation— — 1,904 — — — 1,904 
Issuance of common stock, net of fees9,333 9 14,087 — — — 14,096 
Net income— — — 82,603 — — 82,603 
Unrealized loss on investments— — — — (277)— (277)
Balance at September 30, 2020117,231 $117 $1,486,853 $(1,394,523)$35 $(4,843)$87,639 

The accompanying notes are an integral part of these condensed consolidated financial statements.



6

Lexicon Pharmaceuticals, Inc.
 
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
Nine Months Ended September 30,
20202019
Cash flows from operating activities:
Net income (loss)$(53,079)$181,271 
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization2,590 2,719 
Stock-based compensation10,594 10,739 
Amortization of debt issuance costs995 1,087 
Deferred tax benefit— (6,014)
Gain on sale of XERMELO assets(132,818)— 
Impairment loss on buildings1,600 — 
Impairment loss on intangible asset— 28,638 
Loss on debt extinguishments, net255 — 
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable52,201 (50,917)
Decrease in inventory345 204 
Increase in prepaid expenses and other current assets(6,008)(3,305)
Decrease in other assets314 330 
Increase (decrease) in accounts payable and other liabilities14,281 (645)
Decrease in deferred revenue— (25,929)
Net cash (used in) provided by operating activities(108,730)138,178 
Cash flows from investing activities:
Purchases of property and equipment(33)(70)
Proceeds from XERMELO sale160,385 — 
Purchases of investments(53,197)(176,987)
Maturities of investments229,500 130,600 
Net cash provided by (used in) investing activities336,655 (46,457)
Cash flows from financing activities:
Repurchase of common stock(1,026)(941)
Repayment of debt borrowings(210,760)(963)
Net cash used in financing activities(211,786)(1,904)
Net increase in cash and cash equivalents16,139 89,817 
Cash and cash equivalents at beginning of period36,112 80,386 
Cash and cash equivalents at end of period$52,251 $170,203 
Supplemental disclosure of cash flow information:
Cash paid for interest$16,892 $13,243 
Supplemental disclosure of non-cash investing and financing activities:
Liabilities assumed by TerSera from the XERMELO sale3,180 — 
Common stock issued in satisfaction of convertible debt exchanges14,096 — 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Lexicon Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
1.           Summary of Significant Accounting Policies
 
Basis of Presentation: The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020.

The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. 
Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
 
Cash, Cash Equivalents and Short-Term Investments: Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.  As of September 30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities. As of December 31, 2019, short-term investments consisted of U.S. treasury bills. The Company’s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.  The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.  Unrealized gains and losses on such securities are reported as a separate component of stockholders’ equity.  Net realized gains and losses, interest and dividends are included in interest income.  The cost of securities sold is based on the specific identification method.
 
Accounts Receivable:  Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.

Inventory: Inventory was comprised of supplies of XERMELO supporting the Company’s commercialization of the product in the United States. Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method. As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively. See Note 3, Asset Sale, for additional information relating to inventory.

Intangible Assets: Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization. During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the “FDA”). Intangible assets with finite lives are amortized using the straight-line method over their estimated lives. As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $19.7 million. During the three and nine months ended September 30, 2020, the remaining net carrying value of $18.5 million for the intangible assets relating to XERMELO was reduced to zero as a result of the Xermelo sale.

Accrued liabilities: Accrued liabilities consisted of the following:
8

As of September 30,As of December 31,
20202019
(in thousands)
Accrued research and development services$50,217 $29,033 
Accrued compensation and benefits6,023 9,644 
Short term lease liability553 553 
Other1,704 2,921 
Accrued liabilities$58,497 $42,151 

Revenue Recognition:

Product Revenues

Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (“Ipsen”). Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer. The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. The Company’s net product revenues reflected the Company’s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts. Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company’s customers and such costs were included in cost of sales.
  
Collaborative Agreements

Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.

At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price. Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.

In agreements in which a license to the Company’s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.

For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related
9

sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

The Company may receive payments from its licensees based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

Cost of Sales: Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. For the three and nine months ended September 30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019, includes $0.4 million and $1.3 million, respectively.

Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.  Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred. Substantial portions of the Company’s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company’s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.
 
Stock-Based Compensation:  The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.  Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.  
 
The fair value of stock options is estimated at the date of grant using the Black-Scholes method.  The Black-Scholes option-pricing model requires the input of subjective assumptions.  Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.  For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price.  The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September 30, 2020 and 2019:
10

 Expected VolatilityRisk-free Interest RateExpected TermDividend
Rate
September 30, 2020:    
Employees91 %1.3 %4— %
Officers and non-employee directors78 %1.4 %8— %
September 30, 2019:
Employees88 %2.2 %4— %
Officers and non-employee directors78 %2.6 %8— %

The following is a summary of stock option activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:
 
 OptionsWeighted Average Exercise Price
 (in thousands) 
Outstanding at December 31, 20197,695 $8.95 
Granted3,445 3.25 
Expired(236)12.91 
Forfeited (1)(1,909)5.71 
Outstanding at September 30, 20208,995 7.35 
Exercisable at September 30, 20205,108 $9.63 
(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.

During the nine months ended September 30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:
 SharesWeighted Average Grant Date
Fair Value
 (in thousands) 
Outstanding at December 31, 20192,830 $6.35 
Granted3,144 3.27 
Vested(1,219)6.56 
Forfeited (1)(1,892)4.13 
Outstanding at September 30, 20202,863 $4.35 
 (1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.

Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.


2.           Recent Accounting Pronouncements
In November 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account. This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606. The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.
11

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.

3.           Asset Sale
In September 2020, the Company completed the sale of its XERMELO® (telotristat ethyl) product and related assets (the “XERMELO sale”) to TerSera Therapeutics LLC (“TerSera”) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020. The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million. The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer. The Company has determined that these amounts are constrained until the achievement, if any, of specific events. If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.

The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company’s operations. For the three and nine months ended September 30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company’s XERMELO operations is $2.1 million and $12.1 million, respectively, and for the three and nine months ended September 30, 2019, the pretax net loss for the Company’s XERMELO operations is $4.1 million and $10.8 million, respectively.
As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $5.7 million, of which $5.5 million was incurred through September 30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

4.           Cash and Cash Equivalents and Investments
 
12

The fair value of cash and cash equivalents and investments held at September 30, 2020 and December 31, 2019 are as follows: 
 As of September 30, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
 (in thousands)
Cash and cash equivalents$52,251 $— $— $52,251 
Securities maturing within one year:    
U.S. treasury securities38,796 40 — 38,836 
Corporate debt securities20,364 1 (6)20,359 
Total short-term investments$59,160 $41 $(6)$59,195 
Total cash and cash equivalents and investments$111,411 $41 $(6)$111,446 
 As of December 31, 2019
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands) 
Cash and cash equivalents$36,112 $— $— $36,112 
Securities maturing within one year:    
U.S. treasury securities235,463 94 (10)235,547 
Total short-term investments$235,463 $94 $(10)$235,547 
Total cash and cash equivalents and investments
$271,575 $94 $(10)$271,659 

There were no realized losses during either of the nine months ended September 30, 2020 and 2019, respectively. The cost of securities sold is based on the specific identification method.

5.            Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

•Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities
•Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities
•Level 3 - significant unobservable inputs
13

The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September 30, 2020 and December 31, 2019.

 Assets and Liabilities at Fair Value as of September 30, 2020
 Level 1Level 2Level 3Total
(in thousands)
Assets
Cash and cash equivalents$52,251 $— $— $52,251 
Short-term investments38,836 20,359 — 59,195 
Total cash and cash equivalents and investments$91,087 $20,359 $— $111,446 

 Assets and Liabilities at Fair Value as of December 31, 2019
 Level 1Level 2Level 3Total
 (in thousands)
Assets
Cash and cash equivalents$36,112 $— $— $36,112 
Short-term investments235,547 — — 235,547 
Total cash and cash equivalents and investments$271,659 $— $— $271,659 

The Company did not have any Level 3 assets or liabilities as of September 30, 2020 or December 31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer. There were no transfers between Level 1 and Level 2 during the periods presented.
The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.
Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.
Refer to Note 9, Impairment Loss on Buildings, for fair value measurement of fixed assets.
6.          Debt Obligations
Convertible Debt. In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the “Convertible Notes”). The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company’s condensed consolidated balance sheets.
In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes. In September 2020, the Company issued 9,332,471 shares of the Company’s common stock and paid $44.0 million in cash, which included $1.1 million of accrued interest, to exchange $67.1 million aggregate principal amount of such Convertible Notes. The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments. As a result, a debt extinguishment gain of $8.4 million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. As of September 30, 2020, the carrying value of the remaining Convertible Notes was $20.0 million.
In October 2020, the Company issued 1,036,484 shares of the Company’s common stock and paid $6.0 million in cash, which included $0.2 million of accrued interest, to exchange an additional $8.8 million aggregate principal amount of such Convertible Notes. As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet.
14

The remaining Convertible Notes are governed by an indenture (the “Indenture”), dated as of November 26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee. The Convertible Notes bear interest at a rate of 5.25% per year, payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2015. The Convertible Notes mature on December 1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.
Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.
If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes. As of September 30, 2020, the balance of unamortized debt issuance costs was $0.13 million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets.
The fair value of the remaining Convertible Notes was $15.4 million as of September 30, 2020 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.
Mortgage Loan.  In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the “Property”). The loan agreement provided for a $12.9 million mortgage on the Property and had a two-year term with a 10-year amortization. The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3 million, which was paid in full in August 2020. At December 31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0 million and is included in current portion of long-term debt. The fair value of the loan agreement approximated its carrying value.  The fair value of the loan agreement was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate.

BioPharma Term Loan.  In December 2017, Lexicon entered into a loan agreement with BioPharma under which $150.0 million was funded in December 2017 (the “BioPharma Term Loan”). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.

The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets. The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020. The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6 million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

The Company’s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas. The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions,
15

investments, transactions with affiliates and subordinated debt. If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.

In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs. The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method. The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.

At December 31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value. The fair value of the BioPharma Term Loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate.


7.            Commitments and Contingencies
 
Legal Proceedings.  On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division. The Company’s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020. The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020. The lawsuit purports to be a class action brought on behalf of purchasers of the Company’s securities during the period from March 11, 2016 through July 29, 2019. The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes. The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.

Sanofi Arbitration. On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (“Sanofi”) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the “Termination Agreement”). In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement. The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement. The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys’ fees and costs.

In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity. 

8.           Collaboration and License Agreements
 
Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.
Ipsen. In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the “Ipsen Agreement”), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the “Licensed Territory”). The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.
Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory. Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan. Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO. Lexicon was responsible for the costs of all clinical
16

trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials. Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September 30, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen’s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen’s first commercial sale in Germany, a $3.8 million milestone upon Ipsen’s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen’s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen’s first commercial sale in Canada. In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6 million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of €72 million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained. Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO. Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen’s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.
The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5 million upfront payments:
•The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;
•The development services Lexicon was performing for XERMELO;
•The obligation to participate in committees which governed the development of XERMELO until commercialization; and
•The obligation to supply commercial supply of XERMELO under a commercial supply agreement.

The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights. In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon. As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations. The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement. The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.
The Company determined that the commercial supply agreement was a contingent deliverable at its onset. There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement. The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.
The Company determined that the initial transaction price was the $24.5 million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement. There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product. As such, the Company did not include those payments in the transaction price. The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation. The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate. The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate. The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development. The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services.
As a result of the allocation, the Company recognized $21.2 million of the $24.5 million in upfront payments for the license in 2014, and an additional $1.4 million in 2015 upon entering into the amendment. The Company recognized the $1.7 million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1 million allocated to the committee participation performance obligation ratably over the period of performance. Milestone payments that were contingent upon the achievement of a substantive milestone were
17

deemed constrained. If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated. Revenue recognized under the Ipsen Agreement was $0.3 million and $3.5 million for the nine months ended September 30, 2020 and 2019, respectively. Royalty revenue of $0.3 million was recognized for each of the nine months ended September 30, 2020 and 2019, respectively.
Sanofi. In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the “Sanofi Agreement”), with Sanofi for the worldwide development of Lexicon’s diabetes drug candidate sotagliflozin. In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.
Effective as of September 9, 2019 (the “Settlement Date”), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.
Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. See Note 7, Commitments and Contingencies, for additional information. In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019. Revenue recognized under the Sanofi Agreement was $286.0 million for the nine months ended September 30, 2019.

9.           Impairment Loss on Buildings
 
In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $11.9 million. The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion. The property did not meet the criteria for classification as held for sale at September 30, 2020. Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $1.6 million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs.

10.    Earnings (Loss) Per Share

The following is a summary of Lexicon’s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.

18

(in thousands, except per share data)Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator:
Net income (loss)$82,603 $226,086 $(53,079)$181,271 
  Add interest on Convertible Notes1,258 1,277 — 3,790 
Adjusted net income (loss)$83,861 $227,363 $(53,079)$185,061 
Denominator:
Shares used in computing net income (loss) per common share, basic107,309 106,272 106,974 106,200 
Add effect of potential dilutive securities:
  Share based compensation awards51 3 — 177 
  Convertible Notes10,192 10,365 — 10,365 
Shares used in computing net income (loss) per common share, diluted117,552 116,640 106,974 116,742 
Net income (loss) per share - basic$0.77 $2.13 $(0.50)$1.71 
Net income (loss) per share - diluted$0.71 $1.95 $(0.50)$1.59 

For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share. The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 11,773 and 10,576, respectively, for the three months ended September 30, 2020 and 2019, and 11,859 and 8,452, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.
19

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Overview
 
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates:

•We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts as a promising approach for the treatment of neuropathic pain, and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which we hold exclusive development and commercialization rights. In preclinical studies, LX9211 demonstrated central nervous system penetration and reduction in pain behavior in multiple models of neuropathic pain, and has been demonstrated not to affect opiate pathways. We have reported top-line results from two Phase 1 clinical trials of LX9211, and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.
•We are developing Zynquista™ (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes, in support of which we completed a Phase 3 program involving approximately 3,000 patients with type 1 diabetes. The FDA has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter. Zynquista has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.
We have recently completed a Phase 3 development program for sotagliflozin in type 2 diabetes involving approximately 5,000 patients across nine studies (exclusive of outcomes studies), and are completing the close-out of two outcomes studies involving approximately 10,500 and 1,200 patients, respectively, with primary endpoints evaluating a composite of total cardiovascular death, hospitalizations for heart failure and urgent visits for heart failure.

•We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug discovery and development programs.
In September 2020, we completed the sale of our XERMELO® (telotristat ethyl) product and related assets to TerSera Therapeutics LLC, or TerSera. We commercially launched XERMELO following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy. In connection with the sale, TerSera assumed responsibility for the continued development of XERMELO as a treatment for biliary tract cancer, currently in a Phase 2 clinical trial. We are eligible to receive development, regulatory and sales milestone payments from TerSera of up to an aggregate of $65 million for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens percentage royalty payments from TerSera on net sales of XERMELO in biliary tract cancer.

Sotagliflozin, XERMELO and compounds from a number of additional drug discovery and development programs originated from our own internal drug discovery efforts, and LX9211 and other compounds targeting AAK1 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.

We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs. We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians. We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.
20


Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses. To date, we have generated a substantial portion of our revenues from a limited number of sources.

Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner; TerSera’s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses; and general and industry-specific economic conditions which may affect research and development expenditures.

Future revenues from our sale of XERMELO to TerSera are uncertain because they depend on the achievement of milestones and payment of royalties we earn from TerSera’s development and commercialization of XERMELO in biliary tract cancer. Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.  We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.  Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.

Since our inception, we have incurred significant losses and, as of September 30, 2020, we had an accumulated deficit of $1.4 billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability.
Critical Accounting Policies
The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.  Actual results could differ from those estimates.  We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.
Recent Accounting Pronouncements
There are no recent accounting pronouncements that have a material impact to our condensed consolidated financial statements.

21

Results of Operations
 
Revenues
 
Total revenues and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Total revenues$6.6 $294.4 $23.8 $313.3 
Dollar decrease$(287.8)$(289.5) 
Percentage decrease(98)%(92)% 
 
•Net product revenue – Net product revenue recognized from the sale of XERMELO in the United States for the three months ended September 30, 2020 decreased 22% to $6.5 million as compared to the corresponding period in 2019, due to the Xermelo sale on September 8, 2020. Net product revenue for the nine months ended September 30, 2020 increased 4% to $23.4 million as compared to the corresponding period in 2019. Revenue from sales of bulk tablets of XERMELO to Ipsen were $1.3 million for the nine months ended September 30, 2019. Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance. Revenue recognition policies require estimates of the aforementioned sales allowances each period.
•Collaborative agreements – Revenue from collaborative agreements for the three and nine months ended September 30, 2019 was $285.9 million and $289.2 million. Revenue from collaborative agreements for the three and nine months ended September 30, 2019 included $260 million from the Termination Agreement with Sanofi and recognition of amounts allocated to the performance obligation for development activities of sotagliflozin in the Sanofi Agreement.

Cost of Sales

Total cost of sales and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Total cost of sales$0.6 $0.6 $1.9 $2.5 
Dollar decrease$0.0 $(0.6)
Percentage decrease0 %(21)%

Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Cost of sales for the nine months ended September 30, 2019 included costs related to the bulk tablet sales to Ipsen. Cost of sales for the three and nine months ended September 30, 2020 includes $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019 includes $0.4 million and $1.3 million, respectively, of amortization of intangible assets relating to XERMELO.

Research and Development Expenses
 
22

Research and development expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions): 
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Total research and development expense$40.1 $26.7 $152.6 $51.3 
Dollar increase$13.5 $101.3  
Percentage increase51 %197 % 
Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.  

•Third-party and other services – Third-party and other services for the three months ended September 30, 2020 increased to $31.7 million from $18.5 million, and for the nine months ended September 30, 2020 increased to $125.9 million from $24.0 million as compared to the corresponding periods in 2019 primarily due to increases in external clinical development costs relating to sotagliflozin subsequent to the termination of our collaboration with Sanofi. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.

•Personnel – Personnel costs for the three months ended September 30, 2020 increased 18% to $5.6 million as compared to the corresponding period in 2019, primarily due to the severance costs related to the reduction in force of our personnel in September 2020, partially offset by the lower costs related to employee salaries and management bonuses. For the nine months ended September 30, 2020, personnel costs decreased 3% to $15.6 million as compared to the corresponding period in 2019, primarily due to lower headcount as a result of the reduction in force, partially offset by the severance costs. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

•Stock-based compensation – Stock-based compensation expense for the three months ended September 30, 2020 decreased 39% to $1.0 million, and for the nine months ended September 30, 2020 decreased 4% to $5.2 million as compared to the corresponding periods in 2019, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.

•Facilities and equipment – Facilities and equipment costs for each of the three months ended September 30, 2020 and 2019 was $0.7 million, and for each of the nine months ended September 30, 2020 and 2019 was $2.0 million.

•Other – Other costs for the three months ended September 30, 2020 increased 14% to $1.2 million, and for the nine months ended September 30, 2020 increased 4% to $4.0 million as compared to the corresponding periods in 2019, primarily due to increases in our insurance costs, partially offset by lower costs of travel.

Selling, General and Administrative Expenses
 
Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):
Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Total selling, general and administrative expense$12.0 $13.9 $40.8 $42.3 
Dollar decrease$(1.9)$(1.5) 
Percentage decrease(14)%(3)%
Selling, general and administrative expenses consist primarily of personnel costs to sell XERMELO and to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.


23

•Personnel – Personnel costs for the three months ended September 30, 2020 increased 17% to $7.7 million, and for the nine months ended September 30, 2020 increased 2% to $21.9 million as compared to the corresponding periods in 2019, primarily due to the severance costs related to the reduction in force of our personnel in September 2020, partially offset by the lower costs related to employee salaries and management bonuses. Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.

•Professional and consulting fees – Professional and consulting fees for the three months ended September 30, 2020 decreased 38% to $2.0 million, and for the nine months ended September 30, 2020 decreased 8% to $8.1 million as compared to the corresponding periods in 2019, primarily due to lower marketing expenses and legal fees.

•Stock-based compensation – Stock-based compensation expense for the three months ended September 30, 2020 decreased 53% to $0.9 million as compared to the corresponding period in 2019, and for each of the nine months ended September 30, 2020 and 2019 was $5.4 million. The decrease was due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.

•Facilities and equipment – Facilities and equipment costs for each of the three months ended September 30, 2020 and 2019 were $0.5 million and for each of the nine months ended September 30, 2020 and 2019 were $1.4 million.

•Other – Other costs for the three months ended September 30, 2020 decreased 45% to $1.0 million, and for the nine months ended September 30, 2020 decreased 26% to $3.9 million as compared to the corresponding periods in 2019, primarily due to decreases in travel expenses due to the COVID-19 pandemic.
Gain on the sale of XERMELO
In September 2020, a gain of $132.8 million was recognized in connection with the sale of XERMELO and related assets to TerSera.
Impairment Loss on Buildings
In the second quarter of 2020, we began negotiations to sell our facilities in the Woodlands, Texas. We recognized an impairment loss of $1.6 million as a result of writing down the buildings to the estimated net selling price.
Impairment Loss on Intangible Asset
In September 2019, an impairment loss of $28.6 million was recognized to an indefinite lived intangible asset associated with the 2010 acquisition of Symphony Icon, due to the decision to terminate research and development activities related to a program for irritable bowel syndrome that was among the assets acquired.
Loss on Debt Extinguishments, Net
Immediately following the closing of the sale of XERMELO and related assets to TerSera in September 2020, we repaid term borrowings of $150.0 million to BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP. A debt extinguishment loss of $8.6 million was recognized.
In September 2020, we entered into separate, privately negotiated exchange agreements to exchange $67.1 million aggregate principal amount of its 5.25% Convertible Senior Notes due 2021, or the Convertible Notes. As a result, a debt extinguishment gain of $8.4 million was recognized.
Interest Expense and Interest and Other Income, Net
Interest Expense.  Interest expense for the three months ended September 30, 2020 and 2019 was $4.1 million and $5.2 million, and for the nine months ended September 30, 2020 and 2019 was $14.4 million and $15.5 million.

Interest and Other Income, Net. Interest and other income, net for the three months ended September 30, 2020 and 2019 was $0.3 million and $0.6 million, respectively, and for the nine months ended September 30, 2020 and 2019 was $1.9 million and $2.1 million, respectively.

Net Income (Loss) and Net Income (Loss) per Common Share

Net income (loss) and Net income (loss) per Common Share. Net income was $82.6 million, or $0.71 per diluted share, in the three months ended September 30, 2020 as compared to $226.1 million, or $1.95 per diluted share, in the
24

corresponding period in 2019. Net loss was $53.1 million, or $0.50 per share, in the nine months ended September 30, 2020 as compared to net income of $181.3 million, or $1.59 per diluted share, in the corresponding period in 2019.
Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.

Liquidity and Capital Resources
We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, third party financing arrangements and financing under debt and lease arrangements.
As of September 30, 2020, we had $111.4 million in cash, cash equivalents and short-term investments. As of December 31, 2019, we had $271.7 million in cash, cash equivalents and short-term investments. We used cash of $108.7 million from operations in the nine months ended September 30, 2020. This consisted primarily of the net loss for the period of $53.1 million and gain from the sale of XERMELO and related assets to TerSera of $132.8 million, partially offset by a net decrease in operating assets net of liabilities of $61.1 million, non-cash charges of $10.6 million related to stock-based compensation expense, $3.6 million related to depreciation and amortization expense, including amortization of debt issuance costs, $1.6 million related to the impairment loss and $0.3 million related to the net loss of debt extinguishments. Investing activities provided cash of $336.7 million in the nine months ended September 30, 2020, primarily due to $176.3 million of net maturities of investments and $160.4 million of proceeds from the sale of XERMELO. Financing activities used cash of $211.8 million, primarily to repay $210.8 million of debt borrowings and to repurchase $1.0 million of common stock.
Other commitments. In April 2019, Zynquista was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. Upon the achievement of certain European regulatory pricing approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million.
In September 2020, we initiated a Phase 2 clinical trial of LX9211 in diabetic peripheral pain. As a result of the commencement of the Phase 2 trial, we were required to make a royalty payment of $2.5 million, which was paid in October 2020.
Facilities. In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $11.9 million. Such sale is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion. Such sale is also subject to the negotiation and execution by the parties of a month-to-month leaseback agreement for up to six months with respect to a portion of the property concurrently with closing.
In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey. The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.
Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner; TerSera’s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.  Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.  We expect to continue to devote substantial capital resources to successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates and for other general corporate activities.  We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.  During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional
25

credit arrangements.  Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.

From time to time, our board of directors may authorize us to repurchase shares of our common stock, repurchase, in cash or common stock, our outstanding convertible notes, or make a cash payment to holders of our convertible notes to induce conversion pursuant to the terms of the convertible notes, in each case, in privately negotiated transactions, publicly announced programs or otherwise. If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders. Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.

Disclosure about Market Risk
 
We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.
We had approximately $111.4 million in cash and cash equivalents and short-term investments as of September 30, 2020. We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12 months. We are not subject to interest rate sensitivity on our outstanding Convertible Notes as they generally have a fixed rate of 5.25% per annum. The Convertible Notes interest is payable in cash semi-annually in arrears and matures in December 2021, unless earlier converted or repurchased in accordance with their terms.
We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk
See “Disclosure about Market Risk” under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” for quantitative and qualitative disclosures about market risk.

Item 4.  Controls and Procedures
Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26


Part II -- Other Information 

Item 1.  Legal Proceedings
 
Securities Class Action Litigation. On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division. Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020. The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020. The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019. The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes. The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.

Sanofi Arbitration. On October 16, 2020, we initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH, or Sanofi, seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019. In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to us under the termination and settlement agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by us under the terms of the termination and settlement agreement. We dispute that at least a significant portion of such costs are properly reimbursable by us under the terms of the termination and settlement agreement and assert that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the termination and settlement agreement. We are seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys’ fees and costs.

Normal Course Legal Proceedings. In addition, we are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.


Item 1A.  Risk Factors
 
The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements. The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Business and Industry
•We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and the initiation of planned clinical trials and other operational impacts, each of which could have a material adverse effect on our business.

•We depend on our ability to obtain regulatory approval in the United States for sotagliflozin in type 1 diabetes. If we fail to obtain such regulatory approval or fail to successfully commercialize sotagliflozin for type 1 diabetes in the United States upon regulatory approval, our business will suffer and our stock price will likely decline.

•We depend on our ability to effectively close out two outcomes studies evaluating the effect of sotagliflozin on cardiovascular death and heart failure and involving approximately 10,500 and 1,200 patients, respectively. If we fail to effectively close out such clinical trials on the anticipated timelines, our cash position will suffer and our stock price will likely decline.

•We depend on TerSera’s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts. If TerSera does not successfully complete such development and commercialization activities, we will not receive milestone payment and royalties relating to such efforts, our cash position will suffer and our stock price will likely decline.
27


•Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.

•Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators’ ability to commercialize products.

•The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.

•If we are unable to establish an effective and specialized sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.

•If we are unable to obtain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.

•We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.

•We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.

•We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.

•Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.

•Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.

•Our competitors may develop products that impair the value of any products that we or our collaborators may develop.

Risks Related to Our Capital Requirements and Financial Results
•We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.

•We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.

•Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.

Risks Related to Our Relationships with Third Parties
•We are significantly dependent upon our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of pharmaceutical products. If we are unable to establish such collaborations or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from pharmaceutical products we develop will be greatly reduced.

•Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.

•We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.
28


•We lack the capability to manufacture materials for nonclinical studies and clinical trials and rely on third parties to manufacture our drug candidates, which may harm or delay our research and development efforts.

Risks Related to Our Intellectual Property
•If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.

•We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development activities. We may not prevail in any such litigation or other dispute or be able to obtain required licenses.

•Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.

•We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.

Risks Related to Employees and Facilities Operations
•If we are unable to manage any future growth, our business, financial condition, results of operations and prospects may be adversely affected.

•The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.

•Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.

•Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.

Risks Related to Environmental and Product Liability
•We have used hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

•Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.

Risks Related to Our Common Stock
•Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.

•Invus has additional rights under our stockholders’ agreement with Invus, L.P. relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters.

•Our stock price may be extremely volatile.

•We are subject to securities litigation, which is expensive and could divert management attention.

•Future sales of our common stock, or the perception that such sales may occur, may depress our stock price.

•Conversion of the Convertible Senior Notes may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.

•If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

29

•We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.

For additional discussion of the risks and uncertainties that affect our business, see “Item 1A. Risk Factors” included in our annual report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission.

Item 5. Other Information

Entry into a Material Definitive Agreement

On October 30, 2020, we entered into an Open Market Sale AgreementSM (the “Agreement”) with Jefferies LLC, as sales agent (the “Jefferies”), pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock, par value $0.001, having an aggregate sales price of up to $50,000,000 (the “Shares”).

We are not obligated to sell any Shares under the Agreement. Subject to the terms and conditions of the Agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations to sell Shares from time to time based upon our instructions, including any price, time or size limits specified by us, subject to certain limitations. Under the Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including block transactions, sales made directly on the Nasdaq Global Select Market or sales made into any other existing trading market of our common stock.

The Shares will be issued pursuant to our shelf registration statement on Form S-3 (Registration No. 333-234568), filed November 7, 2019 and effective as of November 18, 2019. We will file a prospectus supplement with the SEC on October 30, 2020 in connection with the offer and sale of the Shares pursuant to the Agreement.

We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of Shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. The Agreement will terminate as set forth in the Agreement.

The foregoing description of the Agreement in this quarterly report on Form 10-Q does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.

Vinson & Elkins L.L.P., our counsel, has issued a legal opinion relating to the validity of the Shares being offered pursuant to the Agreement. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this quarterly report on Form 10-Q and is incorporated herein by reference.

This quarterly report on Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Agreement nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
30

Item 6.  Exhibits

Exhibit No. Description
*1.1—
*5.1—
†10.1—Asset Purchase and Sale Agreement, dated July 29, 2020, with TerSera Therapeutics LLC (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K dated September 8, 2020 and incorporated by reference herein).
10.2—First Amendment to Asset Purchase and Sale Agreement, dated August 10, 2020, with TerSera Therapeutics LLC (filed as Exhibit 2.2 to the Company’s Current Report on Form 8-K dated September 8, 2020 and incorporated by reference herein).
*23.1—Consent of Vinson & Elkins L.L.P (included in Exhibit 5.1)
*31.1
—
*31.2
—
*32.1
—
101.INS
—XBRL Instance Document
101.SCH
—XBRL Taxonomy Extension Schema Document
101.CAL
—XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
—XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
—XBRL Taxonomy Extension Label Linkbase Document
101.PRE
—XBRL Taxonomy Extension Presentation Linkbase Document
_____________________
*Filed herewith.
† In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.


31

Signatures
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 Lexicon Pharmaceuticals, Inc.
   
Date:October 30, 2020By:/s/ Lonnel Coats
  Lonnel Coats
  President and Chief Executive Officer

Date:October 30, 2020By:/s/ Jeffrey L. Wade
  Jeffrey L. Wade
  Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer



32
 EX-1.1 2 exh11openmarketsaleagr.htm EX-1.1 Document

Exhibit 1.1

OPEN MARKET SALE AGREEMENTSM1
    October 30, 2020
JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
Ladies and Gentlemen:
Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
Section 1.DEFINITIONS
(a)Certain Definitions. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings:
“Affiliate” of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
“Agency Period” means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to ‎Section 7.
“Commission” means the U.S. Securities and Exchange Commission.
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.
“Floor Price” means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent’s sole discretion.
SM “Open Market Sale Agreement” is a service mark of Jefferies LLC


“Issuance Amount” means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.
“Issuance Notice” means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as Exhibit A that is executed by its Chief Executive Officer, President or Chief Financial Officer.
“Issuance Notice Date” means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to ‎Section 3(b)(i).
“Issuance Price” means the Sales Price less the Selling Commission.
“Maximum Program Amount” means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company’s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).
“Person” means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.
“Principal Market” means The Nasdaq Global Select Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.
“Sales Price” means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.
“Selling Commission” means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.
“Settlement Date” means the second business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.
“Shares” shall mean the Company’s Common Shares issued or issuable pursuant to this Agreement.
“Trading Day” means any day on which the Principal Market is open for trading.
2

Section 2.REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date and (5) as of each Time of Sale (each of the times referenced above is referred to herein as a “Representation Date”), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date:
(a)Registration Statement. The Company has prepared and filed with the Commission a shelf registration statement on Form S-3 (File No. 333- 234568) that contains a base prospectus (the “Base Prospectus”). Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as the “Registration Statement,” and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the “Prospectus,” except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term “Prospectus” shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use. The Registration Statement at the time it originally became effective is herein called the “Original Registration Statement.” As used in this Agreement, the terms “amendment” or “supplement” when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference.
All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date.
3

At the time the Original Registration Statement was declared effective and at the time the Company’s most recent annual report on Form 10-K was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form S-3 under the Securities Act.
(b)Compliance with Registration Requirements. The Original Registration Statement and any Rule 462(b) Registration Statement have been declared effective by the Commission under the Securities Act. The Company has complied to the Commission’s satisfaction with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission.
The Prospectus when filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (“EDGAR”) (except as may be permitted by Regulation S T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the “Time of Sale Information”) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in Section 6 below. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.
(c)Ineligible Issuer Status. The Company is not an “ineligible issuer” in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the
4

requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent’s prior consent, prepare, use or refer to, any Free Writing Prospectus.
(d)Incorporated Documents. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable.
(e)Exchange Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act.
(f)Statistical and Market-Related Data. All statistical, demographic and market-related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company’s good faith estimates that are made on the basis thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources.
(g)Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. Except as otherwise disclosed in the Prospectus, the Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities, within the time periods specified in the Commission's rules and forms; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its
5

most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
(h)This Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(i)Authorization of the Shares. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and, except as described in the Registration Statement and the Prospectus, the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares.
(j)No Applicable Registration or Other Similar Rights. Except otherwise disclosed in the Prospectus, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.
(k)No Material Adverse Change. Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus: (i) there has been no material adverse change, or any development that could be reasonably expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”); ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.
(l)Independent Accountants. Ernst & Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of
6

accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.
(m)Financial Statements. The financial statements filed with the Commission as a part of the Registration Statement and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders’ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto in all material respects. No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. The financial data set forth in each of the Registration Statement and the Prospectus under the caption “Selected Financial Data” fairly present in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement and the Prospectus.
(n)Company’s Accounting System. Except as otherwise disclosed in the Prospectus, the Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission's rules and guidelines applicable thereto.
(o)Incorporation and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change.
(p)Subsidiaries. Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or
7

organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus. Each of the Company’s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Prospectus, are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary as defined under Rule 1-02 of Regulation S-X other than the subsidiaries listed in Exhibit 21 to the Company’s most recent Annual Report on Form 10-K.
(q)Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement and the Prospectus under the caption “Capitalization” (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Prospectus). The Common Shares (including the Shares) conform in all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding Common Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the Prospectus.
(r)Stock Exchange Listing. The Common Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing. To the Company’s knowledge, it is in compliance in all material respects with all applicable listing requirements of the Principal Market.
(s)Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
8

(“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the Shares will not contravene (i) the provisions of the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii) any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii) any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries; except, in the case of clauses (ii) and (iii), as would not reasonably be expected to result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, except such as (i) have been obtained or made by the Company and are in full force and effect under the Securities Act, (ii) as may be required under applicable state securities or blue sky laws or FINRA (as defined below) and (iii) if not obtained, have not or would not reasonably be expected to result in a Material Adverse Change.
(t)No Material Actions or Proceedings. Except as otherwise disclosed in the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company exists, except as described in the Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change.
(u)Intellectual Property Rights. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, “Intellectual Property”) and, to the Company’s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The Intellectual Property owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company’s knowledge: (i) except as otherwise disclosed in the Prospectus and with respect to LX9211 (to which the Company owns an exclusive license), there
9

are no third parties who have ownership, royalty, or exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii) there is no material infringement by third parties of any Intellectual Property owned by the Company. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property licensed to the Company; (B) challenging the validity, enforceability or scope of any Intellectual Property owned by the Company; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are, to the Company’s knowledge, in full force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company’s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been materially complied with. The product candidates described in the Registration Statement and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.
(v)All Necessary Permits, etc. Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement or the Prospectus (“Permits”), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.
(w)Title to Properties. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by
10

the Company. Except as otherwise disclosed in the Prospectus, the real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.
(x)Tax Law Compliance. Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries (i) have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii) have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with generally accepted accounting principles.
(y)Company Not an “Investment Company.” The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement or the Prospectus, required to register as an “investment company” under the Investment Company Act of 1940, as amended (the “Investment Company Act”).
(z)Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change, except as described in the Prospectus.
(aa)No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Shares or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares or otherwise.
(ab)Related Party Transactions. There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required.
(ac)FINRA Matters. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct.
(ad)No Unlawful Contributions or Other Payments. Except as otherwise disclosed in the Prospectus, neither the Company nor any of its subsidiaries nor, to the best of the Company’s
11

knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus.
(ae)Compliance with Environmental Laws. Except as described in the Prospectus and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by any governmental authority (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for their operations has currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii) the Company and its subsidiaries has not received written notice of any pending or threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice.
(af)ERISA Compliance. Except as would not, individually or in the aggregate, result in a Material Adverse Change: (i) the Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA; “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member; (ii) no “reportable event” (as defined under ERISA), other than an event for which the 30-day notice period is waived, has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (iii) no “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA); (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (b) Sections 412, 4971, 4975 or 4980B of the Code; and (v) each “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether
12

by action or failure to act, which would reasonably be expected to cause the loss of such qualification.
(ag)Brokers. Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.
(ah)Compliance with Laws. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change.
(ai)Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
(aj)Money Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(ak)Clinical Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are, to the Company’s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and
13

scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) except where failure to do so would not result in a Material Adverse Change; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus.
(al)Sanctions. Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.
(am)Sarbanes-Oxley. The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.
(an)Duties, Transfer Taxes, Etc. No stamp or other issuance or transfer taxes or duties are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares.
(ao)Cybersecurity. The Company’s and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, and databases (collectively, “IT
14

Systems”) are reasonably adequate for the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, or bank account information; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by GDPR (as defined below); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. In the past three (3) years, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person under Privacy Laws (as defined below).
(ap)Compliance with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in material compliance with, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with the Company’s policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company further certifies that neither it nor any subsidiary: (i) has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii) is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or liability under any Privacy Law.
(aq)Other Underwriting Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at the market” or continuous equity transaction.
(ar)Compliance with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws, except to the extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health
15

Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.
The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to Section 4(o) hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.
16

Section 3.ISSUANCE AND SALE OF COMMON SHARES
(a)Sale of Securities. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.
(b)Mechanics of Issuances.
(i)Issuance Notice. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in ‎Section 5(a) and Section 5(b) shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; provided, however, that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time.
(ii)Agent Efforts. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification.
(iii)Method of Offer and Sale. The Shares may be offered and sold (A) in negotiated transactions with the consent of the Company or (B) by any other method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clause (A) above) the method of placement of any Shares by the Agent shall be at the Agent’s discretion.
(iv)Confirmation to the Company. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of
17

shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.
(v)Settlement. Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of ‎Section 5, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee’s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a “Time of Sale”).
(vi)Suspension or Termination of Sales. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate; provided, however, that (A) such suspension and termination shall not affect or impair either party’s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with ‎Section 3(b)(v) with respect to such Shares; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to Section 3(b)(i).
(vii)No Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.
(viii)Material Non-Public Information. Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.
18

(c)Fees. As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to Section 3(b)(vi)) by the Agent deducting the Selling Commission from the applicable Issuance Amount.
(d)Expenses. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the original issuance of the Shares; (iv) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, attorneys’ fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a “Blue Sky Survey” or memorandum and a “Canadian wrapper”, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii) the reasonable fees and disbursements of the Agent’s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent’s participation in the offering and distribution of the Shares; (viii) the filing fees incident to FINRA review, if any; (ix) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show; and (x) the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent’s counsel pursuant to subsections (vi) and (vii) above shall not exceed (A) $50,000 in connection with execution of this Agreement and (B) $15,000 in connection with each Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to Section 4(o).
Section 4.ADDITIONAL COVENANTS
The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:
19

(a)Exchange Act Compliance. During the Agency Period, the Company shall file, on a timely basis, with the Commission all reports and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and either include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or, in the Company’s sole discretion, prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an “Interim Prospectus Supplement”), such summary information and, at least once a quarter and subject to this Section 4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)).
(b)Securities Act Compliance. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its commercially reasonable efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission.
(c)Amendments and Supplements to the Prospectus and Other Securities Act Matters. If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to Section 4(d) and Section 4(f)) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply
20

with applicable law including the Securities Act. Neither the Agent’s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under Section 4(d) and Section 4(f). Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interest not to file such amendment or supplement.
(d)Agent’s Review of Proposed Amendments and Supplements. Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) under the Securities Act), insofar as such proposed amendment or supplement relates to the Shares, or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent, and the Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
(e)Use of Free Writing Prospectus. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party’s prior written consent, any “written communication” that constitutes a “free writing prospectus” as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a “Free Writing Prospectus”).
(f)Free Writing Prospectuses. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company insofar as such proposed amendment or supplement relates to the Shares or the transactions contemplated hereby, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Agent’s consent, which shall not be unreasonably withheld, conditioned or delayed. The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company insofar as such proposed amendment or supplement relates to the Shares or the transactions contemplated hereby, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a
21

material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Agent’s consent, which shall not be unreasonably withheld, conditioned or delayed.
(g)Filing of Agent Free Writing Prospectuses. The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.
(h)Copies of Registration Statement and Prospectus. After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies (which may be electronic copies) of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.
(i)Blue Sky Compliance. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such
22

qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its commercially reasonable efforts to obtain the withdrawal thereof as soon as practicable.
(j)Earnings Statement. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act; provided that the Company will be deemed to have furnished such statement to its security holders and the Agent to the extent such statement is filed with the Commission on EDGAR or any successor system.
(k)Listing; Reservation of Shares. The Company will use commercially reasonable efforts to (a) maintain the listing of the Shares on the Principal Market; and (b) reserve and keep available at all times, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.
(l)Transfer Agent. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.
(m)Due Diligence. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and, upon reasonable notice, making available documents and senior corporate officers, during normal business hours and at the Company’s principal offices, as the Agent may reasonably request from time to time.
(n)Representations and Warranties. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii) an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).
23

(o)Deliverables at Triggering Event Dates; Certificates. The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:
(1)the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus;
(2)the filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K/A or Form 10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly report on Form 10-Q), in each case, of the Company; or
(3)the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information “furnished” pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent’s reasonable discretion;
(any such event, a “Triggering Event Date”), the Company shall furnish the Agent (but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material to a holder of Common Shares and informs the Company in writing of such determination) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in Section 5(a)(iii) hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this Section 4(o) shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section 4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this Section 4(o) dated as of the date that the instructions for the sale of Shares are issued.
24

(p)Legal Opinions. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Vinson & Elkins LLP, counsel to the Company, Brian T. Crum, Vice President and General Counsel of the Company and Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, each dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date).
(q)Comfort Letter. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause Ernst & Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company’s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form 10-K or a quarterly report on Form 10-Q.
(r)Secretary’s Certificate. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request.
25

(s)Agent’s Own Account; Clients’ Account. The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent’s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.
(t)Investment Limitation. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.
(u)Market Activities. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (“Rule 102”) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102.
(v)Notice of Other Sale. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other “at the market” or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the Company’s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) issuance or sale of Common Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers,
26

acquisitions, other business combinations, joint ventures or strategic alliances occurring after the date of this Agreement which are not used for capital raising purposes; provided, that the aggregate number of Common Shares or securities convertible into or exchangeable for Common Shares issued in connection with all such acquisitions and other transactions does not exceed 5% of the aggregate number of Common Shares outstanding immediately following the offering of Shares pursuant to this Agreement and (vi) modification of any outstanding options, warrants of any rights to purchase or acquire Common Shares.
Section 5.CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT
(a)Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares. The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions:
(a)Accuracy of the Company’s Representations and Warranties; Performance by the Company. The Company shall have delivered the certificate required to be delivered pursuant to Section 4(o) on or before the date on which delivery of such certificate is required pursuant to Section 4(o). The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in ‎Section 4(p), Section 4(q) and Section 4(r).
(b)No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.
(c)Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.
(d)No Suspension of Trading in or Delisting of Common Shares; Other Events. The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and
27

shall not have been delisted from the Nasdaq Stock Market, the New York Stock Exchange or any of their constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses (i) and (ii) below) any of the following: (i) trading or quotation in any of the Company’s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on either the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii) a general banking moratorium shall have been declared by any of federal or New York, authorities; or (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. Additionally, the Company shall meet the then-applicable requirements for use of Form S-3 under the Securities Act, which, for the avoidance of doubt, will consist of the Registrant Requirements under General Instructions I. A of Form S-3 and one or more of the Transaction Requirements under General Instructions I.B of Form S-3 pursuant to which the Shares may be issued and sold.
(b)Documents Required to be Delivered on each Issuance Notice Date. The Agent’s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice).
(c)No Misstatement or Material Omission. Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Times of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s reasonable opinion is material, or omits to state a fact that in the Agent’s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.
(d)Agent Counsel Legal Opinion. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to Section 4(p), with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters.
Section 6.INDEMNIFICATION AND CONTRIBUTION
(a)Indemnification of the Agent. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage,
28

liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any and all expenses (including the fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b) below. The indemnity agreement set forth in this ‎Section 6(a) shall be in addition to any liabilities that the Company may otherwise have.
(b)Indemnification of the Company, its Directors and Officers. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the
29

circumstances under which they were made, not misleading; but, for each of (i) and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption “Plan of Distribution” in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all reasonable and documented expenses (including the reasonable and documented fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section 6(b) shall be in addition to any liabilities that the Agent or the Company may otherwise have.
(c)Notifications and Other Indemnification Procedures. Promptly after receipt by an indemnified party under this ‎Section 6 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this ‎Section 6, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this ‎Section 6 or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 6 for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the
30

indemnified party (in the case of counsel for the indemnified parties referred to in ‎Section 6(a) and Section 6(b) above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.
(d)Settlements. The indemnifying party under this ‎Section 6 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section 6(c) hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.
(e)Contribution. If the indemnification provided for in this ‎Section 6 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state
31

a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in ‎Section 6(c), any reasonable and documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in ‎Section 6(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this ‎Section 6(e); provided, however, that no additional notice shall be required with respect to any action for which notice has been given under ‎Section 6(c) for purposes of indemnification.
The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this ‎Section 6(e) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this ‎‎Section 6(e).
Notwithstanding the provisions of this ‎‎Section 6(e), the Agent shall not be required to contribute any amount in excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this ‎‎Section 6(e), each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.
Section 7.TERMINATION & SURVIVAL
(a)Term. Subject to the provisions of this ‎Section 7, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this ‎Section 7.
(b)Termination; Survival Following Termination.
(i)Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days’ notice to the other party; provided that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with ‎Section 3(b)(v) with respect to such Shares and (B) ‎Section 2, Section 3(d), Section 6, Section 7 and Section 8 shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.
32

(ii)In addition to the survival provision of ‎Section 7(b)(i), the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.
Section 8.MISCELLANEOUS
(a)Press Releases and Disclosure. The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8 K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (except any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.
(b)No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm’s-length commercial transactions between the Company and the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.
(c)Research Analyst Independence. The Company acknowledges that the Agent’s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal
33

policies, and as such the Agent’s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.
(d)Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:
If to the Agent:
Jefferies LLC
520 Madison Avenue
New York, NY 10022
Facsimile: (646) 786-5719
Attention: General Counsel
with a copy (which shall not constitute notice) to:
Cooley LLP
55 Hudson Yards
New York, NY 10001
Attention: Daniel I. Goldberg, Esq.
Facsimile: (212) 479-6275
If to the Company:
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, Texas 77381
Attention: Brian T. Crum
Facsimile: 281-863-8010

with a copy (which shall not constitute notice) to:
Vinson & Elkins LLP
1001 Fannin Street, Suite 2500
Houston, Texas 77002
Attention: David Oelman
Facsimile: (713) 615-5861

Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this Section 8(d).
34

(e)Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in Section 6, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.
(f)Partial Unenforceability. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
(g)Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.
(h)General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

35

[Signature Page Immediately Follows]

36

If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms
Very truly yours,
LEXICON PHARMACEUTICALS, INC.
By:     /s/ Jeffrey L. Wade
    Name: Jeffrey L. Wade
    Title: CFO & EVP Corp & Admin Affairs        
The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.
JEFFERIES LLC
By:     /s/ Dustin Tyner
    Name: Dustin Tyner
    Title: Managing Director



EXHIBIT A
ISSUANCE NOTICE
[Date]
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Attn: [__________]
Reference is made to the Open Market Sale AgreementSM between Lexicon Pharmaceuticals, Inc. (the “Company”) and Jefferies LLC (the “Agent”) dated as of October [●], 2020. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.
Date of Delivery of Issuance Notice (determined pursuant to Section 3(b)(i)):
_______________________
Issuance Amount (equal to the total Sales Price for such Shares):
    $    
Number of days in selling period:        
First date of selling period:        
Last date of selling period:        
Settlement Date(s) if other than standard T+2 settlement:
        
Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent’s sole discretion): $ ____ per share
Comments:         
        
By:         
    Name:
    Title:


Schedule A
Notice Parties
The Company
1.Jeff Wade – Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer

2.Brian Crum – Vice President and General Counsel

3.Jim Tessmer – Vice President, Finance and Accounting


The Agent
1.Donald Lynaugh - Managing Director

2.Michael Magarro - Managing Director

3.Dustin Tyner - Managing Director



 EX-5.1 3 exh51veopinion10-30x20.htm EX-5.1 Document

Vinson & Elkins LLP Letterhead                                    Exhibit 5.1


October 30, 2020

Lexicon Pharmaceuticals, Inc.
800 Technology Forest Place
The Woodlands, TX 77381
Ladies and Gentlemen:
We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with respect to certain legal matters in connection with the proposed issuance and sale from time to time by the Company of common stock, par value $0.001 (the “Common Stock”), having an aggregate offering price of up to $50,000,000 (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated October 30, 2020 (the “Sales Agreement”) between the Company and Jefferies LLC. We have participated in the preparation of a Prospectus Supplement dated October 30, 2020 (the “Prospectus Supplement”), forming part of the Registration Statement on Form S-3, effective as of November 18, 2019 (the “Registration Statement”), that also contains a base prospectus (the “Base Prospectus” and, together with the Prospectus Supplement, the “Prospectus”). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act.
In rendering the opinions set forth below, we have examined and relied upon (i) the Registration Statement and the Prospectus; (ii) the Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii) the Second Amended and Restated Bylaws of the Company, as amended to the date hereof; (iv) the Sales Agreement; (v) resolutions of the Board of Directors of the Company dated October 23 and 24, 2019 and October 22, 2020; and (vi) such other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed.
In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the Sales Agreement.
Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth below, we are of the opinion that the Shares, when issued and delivered against payment therefore in accordance with the Sales Agreement, will be validly issued, fully paid and non-assessable, except as described in the Registration Statement and the Prospectus.
The opinions expressed herein are qualified in the following respects:
A. We have assumed that (i) each document submitted to us for review is accurate and complete, each such document that is an original is authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii) each certificate from governmental officials reviewed by us is accurate, complete and authentic, and all official public records are accurate and complete.


B. This opinion is limited in all respects to the federal laws of the United States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other jurisdiction.

Very truly yours,
/s/ Vinson & Elkins L.L.P.
Vinson & Elkins L.L.P.


 EX-31.1 4 exh311certificationofp.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATIONS
I, Lonnel Coats, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 30, 2020
/s/ Lonnel Coats
Lonnel Coats
President and Chief Executive Officer


 EX-31.2 5 exh312certificationofp.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS
I, Jeffrey L. Wade, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 30, 2020

/s/ Jeffrey L. Wade
Jeffrey L. Wade
Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer


 EX-32.1 6 exh321certificationofp.htm EX-32.1 Document



Exhibit 32.1
CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (“Lexicon”), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that:
1.Lexicon's Quarterly Report on Form 10-Q for the period ended September 30, 2020, and to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and
2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.
IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 30th day of October, 2020.

By:/s/ Lonnel Coats
Lonnel Coats
President and Chief Executive Officer


By:/s/ Jeffrey L. Wade
Jeffrey L. Wade
Executive Vice President, Corporate and Administrative
Affairs and Chief Financial Officer




EX-101.SCH 7 lxrx-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets-Unaudited link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets Parentheticals link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of Significant Accounting Policies (Notes) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes) link:presentationLink link:calculationLink link:definitionLink 0402407 - Document - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2111103 - Disclosure - Asset Sale (Notes) link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - Asset Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Cash and Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2318303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Debt Obligations link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Debt Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2125108 - Disclosure - Collaboration and License Agreements link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Collaboration and License Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2427414 - Disclosure - Collaboration and License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - Impairment Loss on Buildings link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - Impairment Loss on Buildings (Tables) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Impairment Loss on Buildings (Details) link:presentationLink link:calculationLink link:definitionLink 2231202 - Disclosure - Comprehensive Text Block List (Policies) link:presentationLink link:calculationLink link:definitionLink 2132110 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2333307 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 lxrx-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 lxrx-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 lxrx-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Receivable Type [Axis] Receivable Type [Axis] Convertible debt exchange Convertible debt exchange Convertible debt exchange Interest and other income, net Other Nonoperating Income (Expense) Decrease in deferred revenue Increase (Decrease) in Deferred Revenue Commitments and Contingencies Disclosure Commitments and Contingencies Disclosure [Text Block] Decrease in accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Stock Treasury Stock [Member] Cost of sales (including finite-lived intangible asset amortization) Cost of Goods and Services Sold Future Convertible debt exchange shares Future Convertible debt exchange shares Future Convertible debt exchange shares Award Date [Domain] Award Date [Domain] Gain on sale of non-financial assets Gain on sale of non-financial assets Gain on sale of non-financial assets Gain on sale of non-financial assets Equity Components [Axis] Equity Components [Axis] Debt Obligations [Abstract] Debt Obligations [Abstract] Debt Obligations [Abstract] SG&A severance costs [Member] SG&A severance costs [Member] SG&A severance costs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fair Value, Level 3 Fair Value, Inputs, Level 3 [Member] Operating Lease, Liability, Current Operating Lease, Liability, Current Debt Issuance Costs, Gross Debt Issuance Costs, Gross Award Date [Axis] Award Date [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Liabilities assumed by TerSera Liabilities assumed by TerSera Liabilities assumed by TerSera Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Revenues: Revenues [Abstract] Security Exchange Name Security Exchange Name Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Share-based Payment Arrangement, Option, Activity [Table Text Block] Share-based Payment Arrangement, Option, Activity [Table Text Block] Accounts Receivable [Member] Accounts Receivable [Member] Proceeds from Convertible Debt Proceeds from Convertible Debt Share-based Payment Arrangement [Policy Text Block] Share-based Payment Arrangement [Policy Text Block] Fair Value Measurements [Abstract] Fair Value Measurements [Abstract] Fair Value Measurements [Abstract] Loss from operations Operating Income (Loss) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term. Total current liabilities Liabilities, Current Accounts Receivable [Policy Text Block] Accounts Receivable [Policy Text Block] Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively Selling, general and administrative expenses Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs. Entity Registrant Name Entity Registrant Name Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Severance Costs Severance Costs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Accrued compensation and benefits current Accrued compensation and benefits current Accrued compensation and benefits current - due within 1 year Asset Impairment Charges Asset Impairment Charges Consolidated Statements of Operations [Abstract] Consolidated Statements of Operations [Abstract] Consolidated Statements of Operations [Abstract] Commitments and contingencies Commitments and Contingencies Repurchase of common stock Payments for Repurchase of Common Stock Schedule of cash and cash equivalents and investments Schedule of Investments [Table] Schedule of Investments [Table] Accounting Policies [Abstract] Entity Address, State or Province Entity Address, State or Province Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Ipsen Maximum Sales Milestones Ipsen Maximum Sales Milestones In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments. Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Accounts payable Accounts Payable, Current future convertible debt exchange future convertible debt exchange future convertible debt exchange Other Commitments [Table] Other Commitments [Table] Mortgage Debt Interest Rate BasePlus_Revere_LXRX Mortgage Debt Interest Rate BasePlus_Revere_LXRX Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5% Fair Value Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Accrued Liabilities [Axis] accrued liabilities [Axis] accrued liabilities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Convertible debt exchange - Total Principal Amount Convertible debt exchange - Total Principal Amount Convertible debt exchange - Total Principal Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Cost of Goods and Service [Policy Text Block] Cost of Goods and Service [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Restructuring Type [Axis] Restructuring Type [Axis] Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Inventory [Abstract] Inventory [Abstract] Inventory [Abstract] Goodwill Goodwill Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors. Total operating expenses Operating Expenses Document Transition Report Document Transition Report Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common stock, par value per share Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Ipsen Revenue Allocated to License Deliverable Ipsen Revenue Allocated to License Deliverable In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable. Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract] Accrued Liabilities [Domain] Accrued Liabilities [Domain] Accrued Liabilities Stock-based compensation expense associated with research and development expense Stock-based compensation expense associated with research and development expense Stock-based compensation expense included in research and development expense. Debt Instrument, Face Amount Debt Instrument, Face Amount Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Fair Value, Level 2 Fair Value, Inputs, Level 2 [Member] Prepaid expenses and other current assets Other Assets, Current Document Quarterly Report Document Quarterly Report Inventory Inventory, Net Vesting [Axis] Vesting [Axis] Collaborative agreements Revenue from Contract with Customer, Excluding Assessed Tax Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Inventory [Line Items] Inventory [Line Items] Equity: Equity [Abstract] Debt Instrument, Convertible, Conversion Ratio Debt Instrument, Convertible, Conversion Ratio Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Ipsen Revenue Recognized Ipsen Revenue Recognized In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. Forecast [Member] Forecast [Member] Net income (loss) per common share, Basic Earnings Per Share, Basic Class of Stock [Domain] Class of Stock [Domain] Ipsen Milestone Payment Ipsen Milestone Payment In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement. Entity File Number Entity File Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Inventory, Current [Table] Inventory, Current [Table] Statement [Table] Statement [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Amortization of debt issuance costs Amortization of Debt Issuance Costs and Discounts Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Preferred stock, shares issued Preferred Stock, Shares Issued Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Repayment of debt borrowings, net of fees Repayments of Long-term Debt Text Block [Abstract] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Cash Flows [Abstract] Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities TerSera Maximum Development, Regulatory and Commercial Milestones TerSera Maximum Development, Regulatory and Commercial Milestones TerSera Maximum Development, Regulatory and Commercial Milestones Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively Common Stock, Value, Issued Entity Small Business Entity Small Business Document Fiscal Year Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Asset Retirement Obligation Disclosure [Abstract] Impairment of Real Estate Impairment of Real Estate Current portion of long-term debt, net of deferred issuance costs Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Unamortized Debt Issuance Expense Unamortized Debt Issuance Expense Debt Disclosure Debt Disclosure [Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Receivable [Domain] Receivable [Domain] Intangible Assets, Net (Including Goodwill) Intangible Assets, Net (Including Goodwill) Amendment Flag Amendment Flag Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Trading Activity, by Type [Domain] Trading Activity, by Type [Domain] Collaborative Arrangement Disclosure Collaborative Arrangement Disclosure [Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued Balance, shares Balance, shares Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Other Accrued Liabilities, Current Other Accrued Liabilities, Current Royalties and other revenue Royalty Income, Nonoperating Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Stock-based compensation expense associated with selling, general and administrative expense Stock-based compensation expense associated with selling, general and administrative expense Stock-based compensation expense associated with selling, general and administrative expense Entity Central Index Key Entity Central Index Key Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Long-term debt, net of deferred issuance costs Long-term Debt, Excluding Current Maturities Xermelo Pretax Net Loss Xermelo Pretax Net Loss Xermelo Pretax Net Loss (Increase) decrease in accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholder's equity (deficit) Stockholders' Equity Attributable to Parent Consolidated Balance Sheets [Abstract] Consolidated Balance Sheets [Abstract] Consolidated Balance Sheets [Abstract] Fair Value, by Balance Sheet Grouping [Table Text Block] Fair Value, by Balance Sheet Grouping [Table Text Block] Sale of Non-Financial Assets Sale of Non-Financial Assets [Text Block] Sale of Non-Financial Assets Total liabilities and equity Liabilities and Equity Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Entity Address, City or Town Entity Address, City or Town Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Convertible debt exchange Remaining Notes Convertible debt exchange Remaining Notes Convertible debt exchange Remaining Notes Equity Component [Domain] Equity Component [Domain] Ipsen Total Payments Ipsen Total Payments In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Convertible debt exchange - September share payment Convertible debt exchange - September share payment Convertible debt exchange - September share payment Cash and Cash Equivalents Cash [Member] Other Commitments [Line Items] Other Commitments [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Amortization of Intangible Assets Amortization of Intangible Assets Net income (loss) Net loss Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Total Cash and Cash Equivalents and Investments Investments [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Inventory, Work in Process, Gross Inventory, Work in Process, Gross Issuance of common stock under Equity Incentive Plans, value Stock Issued During Period, Value, New Issues Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Convertible debt exchange - September principal amount Convertible debt exchange - September principal amount Convertible debt exchange - September principal amount Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Statement, Scenario [Axis] Scenario [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Mortgage Debt Instrument_Revere_LXRX Mortgage Debt Instrument_Revere_LXRX Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Trading Activity, by Type [Axis] Trading Activity [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrealized gain on investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Vesting [Domain] Vesting [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Interest expense Interest Expense Ipsen Total Upfront Payments Ipsen Total Upfront Payments In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement. Depreciation and amortization Depreciation, Depletion and Amortization Total Short-term Investments Short-term Investments [Member] Accrued Liabilities Accrued Liabilities Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets Total liabilities Liabilities Investment [Axis] Investment Type [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees The expected term assumption that is used in valuing an option on its own shares for employees. Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Sanofi termination cash payment lxrx_Sanofi termination cash payment lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance Fair Value, Level 1 Fair Value, Inputs, Level 1 [Member] Inventory [Domain] Inventory [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term. (Increase) decrease in inventory Increase (Decrease) in Inventories Convertible debt exchange- September cash portion Convertible debt exchange- September cash portion Convertible debt exchange- September cash portion U.S. Treasury Securities US Treasury Securities [Member] Ipsen Revenue Allocated to Development Deliverable Ipsen Revenue Allocated to Development Deliverable In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable. Issuance of common stock under Equity Incentive Plans, shares Stock Issued During Period, Shares, New Issues principal amount of convertible notes principal amount of convertible notes principal amount of convertible notes Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Short-term Investments Available-for-sale Securities Accrued research and development services current Accrued research and development services current Accrued research and development services current Mortgage Debt Interest Rate_Base_Revere_LXRX Mortgage Debt Interest Rate_Base_Revere_LXRX Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5% Accumulated depreciation and amortization, property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accrued Liabilities [Table] accrued liabilities [Table] accrued liabilities [Table] Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method BioPharma [Member] BioPharma [Member] BioPharma Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement, Option [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Shares used in computing net loss per common share, Basic Weighted Average Number of Shares Outstanding, Basic Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee The risk-free interest rate assumption that is used in valuing an option on its own shares for employees. Net Income (Loss) before Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively Research and Development Expense Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Ipsen Milestone Payment Received Ipsen Milestone Payment Received In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period. Treasury stock, shares Treasury Stock, Shares Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Subsequent Event [Member] Subsequent Event [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares authorized Common Stock, Shares Authorized Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Plan Name [Domain] Plan Name [Domain] R&D severance costs [Member] R&D severance costs [Member] R&D severance costs Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Income Tax Benefit Deferred Federal Income Tax Expense (Benefit) Equity Option [Member] Equity Option [Member] Revenue [Policy Text Block] Revenue [Policy Text Block] Balance, value Balance, value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Additional paid-in capital Additional Paid in Capital Cash and Cash Equivalents and Investments [Abstract] Cash and Cash Equivalents and Investments [Abstract] Cash and Cash Equivalents and Investments [Abstract] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Total revenues Revenues Class of Stock [Axis] Class of Stock [Axis] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Accrued liabilities Accrued Liabilities, Current (Increase) decrease in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Net income (loss) per common share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted Local Phone Number Local Phone Number Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block] Cash, Cash Equivalents and Investments [Table Text Block] Summary of Significant Accounting Policies [Abstract] Summary of Significant Accounting Policies [Abstract] Summary of Significant Accounting Policies [Abstract] Conv Debt Instrument Interest Rate Stated Percentage Conv Debt Instrument Interest Rate Stated Percentage Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] lxrx_sanofi initial cash payment lxrx_sanofi initial cash payment lxrx_sanofi initial cash payment Cash and Cash Equivalents Disclosure Cash and Cash Equivalents Disclosure [Text Block] Current assets: Assets, Current [Abstract] Entity Address, Address Line One Entity Address, Address Line One Total Cash and Cash Equivalents and Investments Investments, Fair Value Disclosure Ipsen Maximum Regulatory And Commercial Milestones Ipsen Maximum Regulatory And Commercial Milestones In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments. Decrease in other assets Increase (Decrease) in Other Operating Assets Entity Emerging Growth Company Entity Emerging Growth Company Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Preferred stock, par value per share Preferred Stock, Par or Stated Value Per Share Award Type [Axis] Award Type [Axis] Realized Investment Gains (Losses) Realized Investment Gains (Losses) Scenario [Domain] Scenario [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Preferred stock, shares authorized Preferred Stock, Shares Authorized Net product revenue Net product revenue Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process. asset sale price asset sale price asset sale price Document Period End Date Document Period End Date Fair Value, Measurement Inputs, Disclosure Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding Preferred Stock, Shares Outstanding accrued interest on convertible accrued interest on convertible accrued interest on convertible Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Purchases of investments Payments to Acquire Investments Sanofi Revenue Recognized Sanofi Revenue Recognized In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Investment [Domain] Investments [Domain] Corporate Debt Securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Accrued Liabilities [Line Items] Accrued Liabilities [Line Items] Accrued Liabilities Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Estimated Fair Value Available-for-sale Securities, Current Treasury stock, at cost, 793 and 407 shares, respectively Treasury Stock, Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors. Debt Issuance Cost Payment of Financing and Stock Issuance Costs Earnings Per Share Earnings Per Share [Text Block] Ipsen Royalty Income_LXRX Ipsen Royalty Income_LXRX Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S. Consolidated Statements of Stockholders’ Equity [Abstract] Consolidated Statements of Stockholders’ Equity [Abstract] Consolidated Statements of Stockholders’ Equity [Abstract] Cover [Abstract] Current liabilities: Liabilities, Current [Abstract] Mortgage Debt Balloon Payment_LXRX Mortgage Debt Balloon Payment_LXRX Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere. Entity Shell Company Entity Shell Company Asset Impairment Charges Asset Impairment Charges [Text Block] Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price New Accounting Pronouncements, Policy New Accounting Pronouncements, Policy [Policy Text Block] Ipsen Revenue Allocated to Committee Deliverable Ipsen Revenue Allocated to Committee Deliverable In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable. Short-term investments Short-term Investments EX-101.PRE 11 lxrx-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 lxrx-20200930_htm.xml IDEA: XBRL DOCUMENT 0001062822 2020-01-01 2020-09-30 0001062822 2020-10-26 0001062822 2020-09-30 0001062822 2019-12-31 0001062822 2019-09-30 0001062822 2020-07-01 2020-09-30 0001062822 2019-07-01 2019-09-30 0001062822 2019-01-01 2019-09-30 0001062822 2020-04-01 2020-06-30 0001062822 us-gaap:CommonStockMember 2018-12-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001062822 us-gaap:RetainedEarningsMember 2018-12-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001062822 us-gaap:TreasuryStockMember 2018-12-31 0001062822 2018-12-31 0001062822 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001062822 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001062822 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001062822 2019-01-01 2019-03-31 0001062822 us-gaap:CommonStockMember 2019-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001062822 us-gaap:RetainedEarningsMember 2019-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001062822 us-gaap:TreasuryStockMember 2019-03-31 0001062822 2019-03-31 0001062822 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001062822 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001062822 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001062822 2019-04-01 2019-06-30 0001062822 us-gaap:CommonStockMember 2019-06-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001062822 us-gaap:RetainedEarningsMember 2019-06-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001062822 us-gaap:TreasuryStockMember 2019-06-30 0001062822 2019-06-30 0001062822 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001062822 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001062822 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001062822 us-gaap:CommonStockMember 2019-09-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001062822 us-gaap:RetainedEarningsMember 2019-09-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001062822 us-gaap:TreasuryStockMember 2019-09-30 0001062822 us-gaap:CommonStockMember 2019-12-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001062822 us-gaap:RetainedEarningsMember 2019-12-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001062822 us-gaap:TreasuryStockMember 2019-12-31 0001062822 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001062822 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001062822 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001062822 2020-01-01 2020-03-31 0001062822 us-gaap:CommonStockMember 2020-03-31 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001062822 us-gaap:RetainedEarningsMember 2020-03-31 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001062822 us-gaap:TreasuryStockMember 2020-03-31 0001062822 2020-03-31 0001062822 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001062822 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001062822 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001062822 us-gaap:CommonStockMember 2020-06-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001062822 us-gaap:RetainedEarningsMember 2020-06-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001062822 us-gaap:TreasuryStockMember 2020-06-30 0001062822 2020-06-30 0001062822 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001062822 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001062822 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001062822 us-gaap:CommonStockMember 2020-09-30 0001062822 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001062822 us-gaap:RetainedEarningsMember 2020-09-30 0001062822 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001062822 us-gaap:TreasuryStockMember 2020-09-30 0001062822 2020-09-01 2020-09-30 0001062822 2020-09-08 0001062822 2017-03-31 0001062822 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001062822 us-gaap:StockOptionMember 2019-01-01 2019-09-30 0001062822 us-gaap:EmployeeStockOptionMember 2019-12-31 0001062822 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001062822 us-gaap:EmployeeStockOptionMember 2020-09-30 0001062822 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001062822 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001062822 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001062822 srt:ScenarioForecastMember 2020-01-01 2020-12-31 0001062822 lxrx:RDSeveranceCostsMember 2020-01-01 2020-09-30 0001062822 lxrx:SGASeveranceCostsMember 2020-01-01 2020-09-30 0001062822 us-gaap:CashMember 2020-09-30 0001062822 us-gaap:USTreasurySecuritiesMember 2020-09-30 0001062822 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001062822 us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001062822 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001062822 us-gaap:InvestmentsMember 2020-09-30 0001062822 us-gaap:CashMember 2019-12-31 0001062822 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001062822 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001062822 us-gaap:InvestmentsMember 2019-12-31 0001062822 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001062822 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001062822 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001062822 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001062822 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001062822 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001062822 2014-11-01 2014-11-30 0001062822 2014-11-20 0001062822 2020-09-28 0001062822 us-gaap:SubsequentEventMember 2020-10-01 0001062822 2018-08-30 0001062822 2017-12-18 0001062822 lxrx:BioPharmaMember 2020-01-01 2020-09-30 0001062822 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001062822 2015-03-01 2015-03-31 0001062822 2017-01-01 2017-03-31 0001062822 2018-01-01 2018-03-31 0001062822 2017-10-01 2017-10-31 0001062822 2017-11-01 2017-11-30 0001062822 2019-10-01 2019-12-31 0001062822 2019-02-01 2019-02-28 0001062822 2014-10-01 2014-10-31 0001062822 2015-01-01 2015-12-31 0001062822 2016-01-01 2016-12-31 shares iso4217:USD iso4217:USD shares pure iso4217:EUR Q3 false 2020 --12-31 0001062822 10-Q true 2020-09-30 false 000-30111 Lexicon Pharmaceuticals, Inc. DE 76-0474169 8800 Technology Forest Place The Woodlands TX 77381 281 863-3000 Common Stock, par value $0.001 LXRX NASDAQ Yes Yes Accelerated Filer false false false 117474808 52251000 36112000 59195000 235547000 1383000 56532000 0 4243000 9109000 5320000 121938000 337754000 63795000 61741000 11106000 14047000 44543000 44543000 0 19716000 1341000 1655000 178928000 417715000 11734000 12178000 58497000 42151000 8691000 11012000 78922000 65341000 11629000 234171000 738000 1102000 91289000 300614000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.001 0.001 225000000 225000000 117231000 106679000 117000 106000 1486853000 1462172000 -1394523000 -1341444000 35000 84000 793000 407000 4843000 3817000 87639000 117101000 178928000 417715000 6542000 8351000 23404000 23763000 0 285910000 33000 289209000 92000 187000 359000 374000 6634000 294448000 23796000 313346000 633000 577000 1929000 2457000 1029000 1698000 5154000 5369000 40147000 26659000 152629000 51318000 875000 1864000 5440000 5370000 11997000 13898000 40798000 42271000 0 0 1600000 0 0 28638000 0 28638000 52777000 69772000 196956000 124684000 132818000 0 132818000 0 86675000 224676000 -40342000 188662000 -255000 0 -255000 0 4118000 5204000 14374000 15485000 301000 600000 1892000 2080000 82603000 220072000 -53079000 175257000 0 -6014000 0 -6014000 82603000 226086000 -53079000 181271000 0.77 2.13 -0.50 1.71 0.71 1.95 -0.50 1.59 107309000 106272000 106974000 106200000 117552000 116640000 106974000 116742000 -277000 -50000 -49000 48000 82326000 226036000 -53128000 181319000 106162000 106000 1447954000 -1471577000 -12000 -2876000 -26405000 0 3411000 0 0 0 3411000 517000 0 0 0 0 0 0 0 0 0 0 941000 941000 0 0 -21797000 0 0 -21797000 0 0 0 45000 0 45000 106679000 106000 1451365000 -1493374000 33000 -3817000 -45687000 0 3766000 0 0 0 3766000 0 0 -23018000 0 0 -23018000 0 0 0 53000 0 53000 106679000 106000 1455131000 -1516392000 86000 -3817000 -64886000 0 3562000 0 0 0 3562000 0 0 226086000 0 0 226086000 0 0 0 -50000 0 -50000 106679000 106000 1458693000 -1290306000 36000 -3817000 164712000 106679000 106000 1462172000 -1341444000 84000 -3817000 117101000 0 4432000 0 0 0 4432000 1032000 2000 0 0 0 0 2000 0 0 0 0 923000 923000 0 0 -66611000 0 0 -66611000 0 0 0 776000 0 776000 107711000 108000 1466604000 -1408055000 860000 -4740000 54777000 0 4258000 0 0 0 4258000 187000 0 0 0 0 0 0 0 0 0 0 103000 103000 0 0 -69071000 0 0 -69071000 0 0 0 -548000 0 -548000 107898000 108000 1470862000 -1477126000 312000 -4843000 -10687000 0 1904000 0 0 0 1904000 9333000 9000 14087000 0 0 0 14096000 0 0 82603000 0 0 82603000 0 0 0 -277000 0 -277000 117231000 117000 1486853000 -1394523000 35000 -4843000 87639000 -53079000 181271000 2590000 2719000 10594000 10739000 995000 1087000 0 -6014000 132818000 0 1600000 0 0 28638000 -255000 0 -52201000 50917000 -345000 -204000 6008000 3305000 -314000 -330000 14281000 -645000 0 -25929000 -108730000 138178000 33000 70000 160385000 0 53197000 176987000 229500000 130600000 336655000 -46457000 1026000 941000 210760000 963000 -211786000 -1904000 16139000 89817000 36112000 80386000 52251000 170203000 16892000 13243000 3180000 14096000 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.  As of September 30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities. As of December 31, 2019, short-term investments consisted of U.S. treasury bills. The Company’s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.  The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.  Unrealized gains and losses on such securities are reported as a separate component of stockholders’ equity.  Net realized gains and losses, interest and dividends are included in interest income.  The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventory was comprised of supplies of XERMELO supporting the Company’s commercialization of the product in the United States. Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method. As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively. See Note 3, Asset Sale, for additional information relating to inventory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization. During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the “FDA”). Intangible assets with finite lives are amortized using the straight-line method over their estimated lives. As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $19.7 million. During the three and nine months ended September 30, 2020, the remaining net carrying value of $18.5 million for the intangible assets relating to XERMELO was reduced to zero as a result of the Xermelo sale. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,497 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (“Ipsen”). Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer. The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. The Company’s net product revenues reflected the Company’s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts. Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company’s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price. Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company’s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. For the three and nine months ended September 30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019, includes $0.4 million and $1.3 million, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.  Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred. Substantial portions of the Company’s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company’s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.  Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.  The Black-Scholes option-pricing model requires the input of subjective assumptions.  Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.  For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price.  The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive. The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.  As of September 30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities. As of December 31, 2019, short-term investments consisted of U.S. treasury bills. The Company’s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.  The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.  Unrealized gains and losses on such securities are reported as a separate component of stockholders’ equity.  Net realized gains and losses, interest and dividends are included in interest income.  The cost of securities sold is based on the specific identification method.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span> Inventory: Inventory was comprised of supplies of XERMELO supporting the Company’s commercialization of the product in the United States. Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method. As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively. 3200000 200000 900000 24700000 19700000 18500000 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,497 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50217000 29033000 6023000 9644000 553000 553000 1704000 2921000 58497000 42151000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (“Ipsen”). Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer. The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. The Company’s net product revenues reflected the Company’s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts. Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company’s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price. Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company’s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related </span></div>sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).The Company may receive payments from its licensees based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. Cost of Sales: Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. For the three and nine months ended September 30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019, includes $0.4 million and $1.3 million, respectively. 300000 1200000 400000 1300000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.  Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred. Substantial portions of the Company’s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company’s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span> <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.  Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.  </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>The fair value of stock options is estimated at the date of grant using the Black-Scholes method.  The Black-Scholes option-pricing model requires the input of subjective assumptions.  Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.  For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.91 0.013 P4Y 0 0.78 0.014 P8Y 0 0.88 0.022 P4Y 0 0.78 0.026 P8Y 0 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7695000 8.95 3445000 3.25 236000 12.91 1909000 5.71 8995000 7.35 5108000 9.63 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2830000 6.35 3144000 3.27 1219000 6.56 1892000 4.13 2863000 4.35 Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive. Recent Accounting PronouncementsIn November 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account. This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606. The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU did not have a material impact on the condensed consolidated financial statements. Asset Sale<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (telotristat ethyl) product and related assets (the “XERMELO sale”) to TerSera Therapeutics LLC (“TerSera”) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020. The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million. The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer. The Company has determined that these amounts are constrained until the achievement, if any, of specific events. If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company’s operations. For the three and nine months ended September 30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company’s XERMELO operations is $2.1 million and $12.1 million, respectively, and for the three and nine months ended September 30, 2019, the pretax net loss for the Company’s XERMELO operations is $4.1 million and $10.8 million, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $5.7 million, of which $5.5 million was incurred through September 30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. 160400000 132800000 65000000 -2100000 -12100000 -4100000 -10800000 5700000 5500000 2500000 3000000.0 Cash and Cash Equivalents and Investments <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at September 30, 2020 and December 31, 2019 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,411 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,575 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the nine months ended September 30, 2020 and 2019, respectively. The cost of securities sold is based on the specific identification method.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,411 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,575 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 52251000 0 0 52251000 38796000 40000 0 38836000 20364000 1000 -6000 20359000 59160000 41000 6000 59195000 111411000 41000 6000 111446000 36112000 0 0 36112000 235463000 94000 10000 235547000 235463000 94000 10000 235547000 271575000 94000 10000 271659000 0 0 Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September 30, 2020 and December 31, 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,087 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of September 30, 2020 or December 31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer. There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.</span></div> <div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,087 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 52251000 0 0 52251000 38836000 20359000 0 59195000 91087000 20359000 0 111446000 36112000 0 0 36112000 235547000 0 0 235547000 271659000 0 0 271659000 Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the “Convertible Notes”). The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company’s condensed consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes. In September 2020, the Company issued 9,332,471 shares of the Company’s common stock and paid $44.0 million in cash, which included $1.1 million of accrued interest, to exchange $67.1 million aggregate principal amount of such Convertible Notes. The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments. As a result, a debt extinguishment gain of $8.4 million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. As of September 30, 2020, the carrying value of the remaining Convertible Notes was $20.0 million. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company issued 1,036,484 shares of the Company’s common stock and paid $6.0 million in cash, which included $0.2 million of accrued interest, to exchange an additional $8.8 million aggregate principal amount of such Convertible Notes. As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining Convertible Notes are governed by an indenture (the “Indenture”), dated as of November 26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee. The Convertible Notes bear interest at a rate of 5.25% per year, payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2015. The Convertible Notes mature on December 1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes. As of September 30, 2020, the balance of unamortized debt issuance costs was $0.13 million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining Convertible Notes was $15.4 million as of September 30, 2020 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the “Property”). The loan agreement provided for a $12.9 million mortgage on the Property and had a two-year term with a 10-year amortization. The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3 million, which was paid in full in August 2020. At December 31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0 million and is included in current portion of long-term debt. The fair value of the loan agreement approximated its carrying value.  The fair value of the loan agreement was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In December 2017, Lexicon entered into a loan agreement with BioPharma under which $150.0 million was funded in December 2017 (the “BioPharma Term Loan”). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets. The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020. The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6 million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas. The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments, transactions with affiliates and subordinated debt. If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs. The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method. The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.</span></div>At December 31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value. The fair value of the BioPharma Term Loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate. 87500000 0.0525 75800000 9332471 44000000.0 1100000 -67100000 8400000 20000000.0 1036484 6000000.0 200000 -8800000 0.0525 118.4553 8.442 3400000 130000 15400000 12900000 0.055 0.075 10300000 11000000.0 150000000.0 0.09 8600000 4100000 Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division. The Company’s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020. The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020. The lawsuit purports to be a class action brought on behalf of purchasers of the Company’s securities during the period from March 11, 2016 through July 29, 2019. The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes. The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (“Sanofi”) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the “Termination Agreement”). In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement. The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement. The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys’ fees and costs.</span></div>In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity. 23200000 26000000 26000000 Collaboration and License Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the “Ipsen Agreement”), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the “Licensed Territory”). The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory. Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan. Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO. Lexicon was responsible for the costs of all clinical </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials. Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September 30, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen’s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen’s first commercial sale in Germany, a $3.8 million milestone upon Ipsen’s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen’s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen’s first commercial sale in Canada. In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6 million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of €72 million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained. Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO. Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen’s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5 million upfront payments: </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The development services Lexicon was performing for XERMELO;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to participate in committees which governed the development of XERMELO until commercialization; and</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to supply commercial supply of XERMELO under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights. In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon. As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations. The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement. The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the commercial supply agreement was a contingent deliverable at its onset. There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement. The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the initial transaction price was the $24.5 million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement. There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product. As such, the Company did not include those payments in the transaction price. The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation. The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate. The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate. The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development. The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the allocation, the Company recognized $21.2 million of the $24.5 million in upfront payments for the license in 2014, and an additional $1.4 million in 2015 upon entering into the amendment. The Company recognized the $1.7 million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1 million allocated to the committee participation performance obligation ratably over the period of performance. Milestone payments that were contingent upon the achievement of a substantive milestone were </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed constrained. If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated. Revenue recognized under the Ipsen Agreement was $0.3 million and $3.5 million for the nine months ended September 30, 2020 and 2019, respectively. Royalty revenue of $0.3 million was recognized for each of the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the “Sanofi Agreement”), with Sanofi for the worldwide development of Lexicon’s diabetes drug candidate sotagliflozin. In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the “Settlement Date”), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div>Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. See Note 7, Commitments and Contingencies, for additional information. In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019. Revenue recognized under the Sanofi Agreement was $286.0 million for the nine months ended September 30, 2019. 47200000 24500000 6400000 5100000 3800000 3800000 1300000 2300000 9600000 72000000 24500000 24500000 21200000 24500000 1400000 1700000 100000 300000 3500000 300000 208000000 208000000 26000000 26000000 286000000.0 286000000.0 Impairment Loss on Buildings In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $11.9 million. The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion. The property did not meet the criteria for classification as held for sale at September 30, 2020. Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $1.6 million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs. 11900000 1600000 Earnings (Loss) Per ShareThe following is a summary of Lexicon’s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:40.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Add interest on Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,363 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,061 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Share based compensation awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share. The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 11,773 and 10,576, respectively, for the three months ended September 30, 2020 and 2019, and 11,859 and 8,452, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div> The following is a summary of Lexicon’s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:40.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Add interest on Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,861 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,363 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,061 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Share based compensation awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 82603000 226086000 -53079000 181271000 1258000 1277000 0 3790000 83861000 227363000 -53079000 185061000 107309000 106272000 106974000 106200000 51000 3000 0 177000 10192000 10365000 0 10365000 117552000 116640000 106974000 116742000 0.77 2.13 -0.50 1.71 0.71 1.95 -0.50 1.59 11773000 10576000 11859000 8452000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2020
Oct. 26, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Fiscal Period Focus Q3  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Amendment Flag false  
Document Fiscal Year Focus 2020  
Current Fiscal Year End Date --12-31  
Entity File Number 000-30111  
Entity Registrant Name Lexicon Pharmaceuticals, Inc.  
Entity Central Index Key 0001062822  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 76-0474169  
Entity Address, Address Line One 8800 Technology Forest Place  
Entity Address, City or Town The Woodlands  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 77381  
City Area Code 281  
Local Phone Number 863-3000  
Title of 12(b) Security Common Stock, par value $0.001  
Trading Symbol LXRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   117,474,808
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets-Unaudited - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 52,251 $ 36,112
Short-term investments 59,195 235,547
Accounts receivable, net 1,383 56,532
Inventory 0 4,243
Prepaid expenses and other current assets 9,109 5,320
Total current assets 121,938 337,754
Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively 11,106 14,047
Goodwill 44,543 44,543
Intangible assets, net 0 19,716
Other assets 1,341 1,655
Total assets 178,928 417,715
Current liabilities:    
Accounts payable 11,734 12,178
Accrued liabilities 58,497 42,151
Current portion of long-term debt, net of deferred issuance costs 8,691 11,012
Total current liabilities 78,922 65,341
Long-term debt, net of deferred issuance costs 11,629 234,171
Other long-term liabilities 738 1,102
Total liabilities 91,289 300,614
Commitments and contingencies
Equity:    
Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively 117 106
Additional paid-in capital 1,486,853 1,462,172
Accumulated deficit (1,394,523) (1,341,444)
Accumulated other comprehensive loss 35 84
Treasury stock, at cost, 793 and 407 shares, respectively (4,843) (3,817)
Total stockholder's equity (deficit) 87,639 117,101
Total liabilities and equity $ 178,928 $ 417,715
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets Parentheticals - USD ($)
shares in Thousands, $ in Thousands
Sep. 30, 2020
Sep. 30, 2019
Consolidated Balance Sheets [Abstract]    
Accumulated depreciation and amortization, property and equipment $ 63,795 $ 61,741
Preferred stock, par value per share $ 0.01 $ 0.01
Preferred stock, shares authorized 5,000 5,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 225,000 225,000
Common stock, shares issued 117,231 106,679
Treasury stock, shares 793 407
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues:        
Net product revenue $ 6,542 $ 8,351 $ 23,404 $ 23,763
Collaborative agreements 0 285,910 33 289,209
Royalties and other revenue 92 187 359 374
Total revenues 6,634 294,448 23,796 313,346
Operating expenses:        
Cost of sales (including finite-lived intangible asset amortization) 633 577 1,929 2,457
Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively 40,147 26,659 152,629 51,318
Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively 11,997 13,898 40,798 42,271
Asset Impairment Charges 0 28,638 0 28,638
Total operating expenses 52,777 69,772 196,956 124,684
Gain on sale of non-financial assets 132,818 0 132,818 0
Loss from operations 86,675 224,676 (40,342) 188,662
Gain (Loss) on Extinguishment of Debt (255) 0 (255) 0
Interest expense (4,118) (5,204) (14,374) (15,485)
Interest and other income, net 301 600 1,892 2,080
Net Income (Loss) before Taxes 82,603 220,072 (53,079) 175,257
Income Tax Benefit 0 6,014 0 6,014
Net income (loss) $ 82,603 $ 226,086 $ (53,079) $ 181,271
Net income (loss) per common share, Basic $ 0.77 $ 2.13 $ (0.50) $ 1.71
Net income (loss) per common share, diluted $ 0.71 $ 1.95 $ (0.50) $ 1.59
Shares used in computing net loss per common share, Basic 107,309 106,272 106,974 106,200
Unrealized gain on investments $ (277) $ (50) $ (49) $ 48
Comprehensive loss 82,326 226,036 (53,128) 181,319
Stock-based compensation expense associated with research and development expense 1,029 1,698 5,154 5,369
Stock-based compensation expense associated with selling, general and administrative expense 875 1,864 5,440 5,370
Impairment of Real Estate $ 0 $ 0 $ 1,600 0
Proceeds from Sale of Productive Assets       $ 0
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Consolidated Statements of Operations [Abstract]        
Stock-based compensation expense associated with research and development expense $ 1,029 $ 1,698 $ 5,154 $ 5,369
Stock-based compensation expense associated with selling, general and administrative expense $ 875 $ 1,864 $ 5,440 $ 5,370
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Treasury Stock
Balance, shares at Dec. 31, 2018   106,162        
Balance, value at Dec. 31, 2018 $ (26,405) $ 106 $ 1,447,954 $ (1,471,577) $ (12) $ (2,876)
Stock-based compensation 3,411 $ 0 3,411 0 0 0
Issuance of common stock under Equity Incentive Plans, shares   517        
Issuance of common stock under Equity Incentive Plans, value 0 $ 0 0 0 0 0
Repurchase of common stock (941) 0 0 0 0 (941)
Net loss   0 0 (21,797) 0 0
Unrealized gain on investments 45 $ 0 0 0 45 0
Balance, shares at Mar. 31, 2019   106,679        
Balance, value at Mar. 31, 2019 (45,687) $ 106 1,451,365 (1,493,374) 33 (3,817)
Balance, shares at Dec. 31, 2018   106,162        
Balance, value at Dec. 31, 2018 (26,405) $ 106 1,447,954 (1,471,577) (12) (2,876)
Net loss 181,271          
Unrealized gain on investments $ 48          
Balance, shares at Sep. 30, 2019 106,679 106,679        
Balance, value at Sep. 30, 2019 $ 164,712 $ 106 1,458,693 (1,290,306) 36 (3,817)
Balance, shares at Mar. 31, 2019   106,679        
Balance, value at Mar. 31, 2019 (45,687) $ 106 1,451,365 (1,493,374) 33 (3,817)
Stock-based compensation 3,766 0 3,766 0 0 0
Net loss   0 0 (23,018) 0 0
Unrealized gain on investments 53 $ 0 0 0 53 0
Balance, shares at Jun. 30, 2019   106,679        
Balance, value at Jun. 30, 2019 (64,886) $ 106 1,455,131 (1,516,392) 86 (3,817)
Stock-based compensation 3,562 0 3,562 0 0 0
Net loss 226,086 0 0 226,086 0 0
Unrealized gain on investments $ (50) $ 0 0 0 (50) 0
Balance, shares at Sep. 30, 2019 106,679 106,679        
Balance, value at Sep. 30, 2019 $ 164,712 $ 106 1,458,693 (1,290,306) 36 (3,817)
Balance, shares at Dec. 31, 2019   106,679        
Balance, value at Dec. 31, 2019 117,101 $ 106 1,462,172 (1,341,444) 84 (3,817)
Stock-based compensation 4,432 $ 0 4,432 0 0 0
Issuance of common stock under Equity Incentive Plans, shares   1,032        
Issuance of common stock under Equity Incentive Plans, value 2 $ 2 0 0 0 0
Repurchase of common stock (923) 0 0 0 0 (923)
Net loss (66,611) 0 0 (66,611) 0 0
Unrealized gain on investments 776 $ 0 0 0 776 0
Balance, shares at Mar. 31, 2020   107,711        
Balance, value at Mar. 31, 2020 54,777 $ 108 1,466,604 (1,408,055) 860 (4,740)
Balance, shares at Dec. 31, 2019   106,679        
Balance, value at Dec. 31, 2019 117,101 $ 106 1,462,172 (1,341,444) 84 (3,817)
Net loss (53,079)          
Unrealized gain on investments $ (49)          
Balance, shares at Sep. 30, 2020 117,231 117,231        
Balance, value at Sep. 30, 2020 $ 87,639 $ 117 1,486,853 (1,394,523) 35 (4,843)
Balance, shares at Mar. 31, 2020   107,711        
Balance, value at Mar. 31, 2020 54,777 $ 108 1,466,604 (1,408,055) 860 (4,740)
Stock-based compensation $ 4,258 0 4,258 0 0 0
Issuance of common stock under Equity Incentive Plans, shares 187          
Issuance of common stock under Equity Incentive Plans, value $ 0 0 0 0 0 0
Repurchase of common stock (103) 0 0 0 0 (103)
Net loss (69,071) 0 0 (69,071) 0 0
Unrealized gain on investments (548) $ 0 0 0 (548) 0
Balance, shares at Jun. 30, 2020   107,898        
Balance, value at Jun. 30, 2020 (10,687) $ 108 1,470,862 (1,477,126) 312 (4,843)
Stock-based compensation $ 1,904 0 1,904 0 0 0
Issuance of common stock under Equity Incentive Plans, shares 9,333          
Issuance of common stock under Equity Incentive Plans, value $ 14,096 9 14,087 0 0 0
Net loss 82,603 0 0 82,603 0 0
Unrealized gain on investments $ (277) $ 0 0 0 (277) 0
Balance, shares at Sep. 30, 2020 117,231 117,231        
Balance, value at Sep. 30, 2020 $ 87,639 $ 117 $ 1,486,853 $ (1,394,523) $ 35 $ (4,843)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net income (loss) $ (53,079) $ 181,271
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,590 2,719
Stock-based compensation 10,594 10,739
Amortization of debt issuance costs 995 1,087
Deferred Income Tax Expense (Benefit) 0 (6,014)
Gain on sale of non-financial assets (132,818) 0
Asset Impairment Charges 0 28,638
Changes in operating assets and liabilities:    
(Increase) decrease in accounts receivable 52,201 (50,917)
(Increase) decrease in inventory 345 204
(Increase) decrease in prepaid expenses and other current assets (6,008) (3,305)
Decrease in other assets 314 330
Decrease in accounts payable and other liabilities 14,281 (645)
Decrease in deferred revenue 0 (25,929)
Net cash provided by (used in) operating activities (108,730) 138,178
Cash flows from investing activities:    
Purchases of property and equipment (33) (70)
Proceeds from Sale of Productive Assets   0
Purchases of investments (53,197) (176,987)
Maturities of investments 229,500 130,600
Net cash (used in) provided by investing activities 336,655 (46,457)
Cash flows from financing activities:    
Repurchase of common stock (1,026) (941)
Repayment of debt borrowings, net of fees (210,760) (963)
Net cash used in financing activities (211,786) (1,904)
Net increase (decrease) in cash and cash equivalents 16,139 89,817
Cash and cash equivalents at beginning of period 36,112 80,386
Cash and cash equivalents at end of period 52,251 170,203
Supplemental disclosure of cash flow information:    
Cash paid for interest 16,892 13,243
Impairment of Real Estate 1,600 0
Gain (Loss) on Extinguishment of Debt $ 255 $ 0
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Notes)
 9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies
 
Basis of Presentation: The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020.

The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the SEC. 
Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
 
Cash, Cash Equivalents and Short-Term Investments: Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.  As of September 30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities. As of December 31, 2019, short-term investments consisted of U.S. treasury bills. The Company’s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.  The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.  Unrealized gains and losses on such securities are reported as a separate component of stockholders’ equity.  Net realized gains and losses, interest and dividends are included in interest income.  The cost of securities sold is based on the specific identification method.
 
Accounts Receivable:  Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.

Inventory: Inventory was comprised of supplies of XERMELO supporting the Company’s commercialization of the product in the United States. Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method. As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively. See Note 3, Asset Sale, for additional information relating to inventory.

Intangible Assets: Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization. During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the “FDA”). Intangible assets with finite lives are amortized using the straight-line method over their estimated lives. As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $19.7 million. During the three and nine months ended September 30, 2020, the remaining net carrying value of $18.5 million for the intangible assets relating to XERMELO was reduced to zero as a result of the Xermelo sale.

Accrued liabilities: Accrued liabilities consisted of the following:
As of September 30,As of December 31,
20202019
(in thousands)
Accrued research and development services$50,217 $29,033 
Accrued compensation and benefits6,023 9,644 
Short term lease liability553 553 
Other1,704 2,921 
Accrued liabilities$58,497 $42,151 

Revenue Recognition:

Product Revenues

Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (“Ipsen”). Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer. The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. The Company’s net product revenues reflected the Company’s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts. Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company’s customers and such costs were included in cost of sales.
  
Collaborative Agreements

Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.

At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price. Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.

In agreements in which a license to the Company’s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.

For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related
sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

The Company may receive payments from its licensees based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

Cost of Sales: Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. For the three and nine months ended September 30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019, includes $0.4 million and $1.3 million, respectively.

Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.  Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred. Substantial portions of the Company’s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company’s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.
 
Stock-Based Compensation:  The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.  Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.  
 
The fair value of stock options is estimated at the date of grant using the Black-Scholes method.  The Black-Scholes option-pricing model requires the input of subjective assumptions.  Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.  For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price.  The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September 30, 2020 and 2019:
 Expected VolatilityRisk-free Interest RateExpected TermDividend
Rate
September 30, 2020:    
Employees91 %1.3 %4— %
Officers and non-employee directors78 %1.4 %8— %
September 30, 2019:
Employees88 %2.2 %4— %
Officers and non-employee directors78 %2.6 %8— %

The following is a summary of stock option activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:
 
 OptionsWeighted Average Exercise Price
 (in thousands) 
Outstanding at December 31, 20197,695 $8.95 
Granted3,445 3.25 
Expired(236)12.91 
Forfeited (1)(1,909)5.71 
Outstanding at September 30, 20208,995 7.35 
Exercisable at September 30, 20205,108 $9.63 
(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.

During the nine months ended September 30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments. The following is a summary of restricted stock units activity under Lexicon’s stock-based compensation plans for the nine months ended September 30, 2020:
 SharesWeighted Average Grant Date
Fair Value
 (in thousands) 
Outstanding at December 31, 20192,830 $6.35 
Granted3,144 3.27 
Vested(1,219)6.56 
Forfeited (1)(1,892)4.13 
Outstanding at September 30, 20202,863 $4.35 
 (1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.
Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Recent Accounting Pronouncements Level 1 (Notes)
 9 Months Ended
Sep. 30, 2020
Recent Accounting Pronouncements [Abstract]  
New Accounting Pronouncements, Policy Recent Accounting PronouncementsIn November 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account. This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606. The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Sale (Notes)
 9 Months Ended
Sep. 30, 2020
Asset Retirement Obligation Disclosure [Abstract]  
Sale of Non-Financial Assets Asset Sale
In September 2020, the Company completed the sale of its XERMELO® (telotristat ethyl) product and related assets (the “XERMELO sale”) to TerSera Therapeutics LLC (“TerSera”) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020. The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million. The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer. The Company has determined that these amounts are constrained until the achievement, if any, of specific events. If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.

The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company’s operations. For the three and nine months ended September 30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company’s XERMELO operations is $2.1 million and $12.1 million, respectively, and for the three and nine months ended September 30, 2019, the pretax net loss for the Company’s XERMELO operations is $4.1 million and $10.8 million, respectively.
As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $5.7 million, of which $5.5 million was incurred through September 30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Cash and Cash Equivalents and Investments
 9 Months Ended
Sep. 30, 2020
Cash and Cash Equivalents and Investments [Abstract]  
Cash and Cash Equivalents Disclosure Cash and Cash Equivalents and Investments 
The fair value of cash and cash equivalents and investments held at September 30, 2020 and December 31, 2019 are as follows: 
 As of September 30, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
 (in thousands)
Cash and cash equivalents$52,251 $— $— $52,251 
Securities maturing within one year:    
U.S. treasury securities38,796 40 — 38,836 
Corporate debt securities20,364 1 (6)20,359 
Total short-term investments$59,160 $41 $(6)$59,195 
Total cash and cash equivalents and investments$111,411 $41 $(6)$111,446 
 As of December 31, 2019
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands) 
Cash and cash equivalents$36,112 $— $— $36,112 
Securities maturing within one year:    
U.S. treasury securities235,463 94 (10)235,547 
Total short-term investments$235,463 $94 $(10)$235,547 
Total cash and cash equivalents and investments
$271,575 $94 $(10)$271,659 

There were no realized losses during either of the nine months ended September 30, 2020 and 2019, respectively. The cost of securities sold is based on the specific identification method.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2020
Fair Value Measurements [Abstract]  
Fair Value, Measurement Inputs, Disclosure Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

•Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities
•Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities
•Level 3 - significant unobservable inputs
The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September 30, 2020 and December 31, 2019.

 Assets and Liabilities at Fair Value as of September 30, 2020
 Level 1Level 2Level 3Total
(in thousands)
Assets
Cash and cash equivalents$52,251 $— $— $52,251 
Short-term investments38,836 20,359 — 59,195 
Total cash and cash equivalents and investments$91,087 $20,359 $— $111,446 

 Assets and Liabilities at Fair Value as of December 31, 2019
 Level 1Level 2Level 3Total
 (in thousands)
Assets
Cash and cash equivalents$36,112 $— $— $36,112 
Short-term investments235,547 — — 235,547 
Total cash and cash equivalents and investments$271,659 $— $— $271,659 

The Company did not have any Level 3 assets or liabilities as of September 30, 2020 or December 31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer. There were no transfers between Level 1 and Level 2 during the periods presented.
The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.
Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Debt Obligations
 9 Months Ended
Sep. 30, 2020
Debt Obligations [Abstract]  
Debt Disclosure Debt Obligations
Convertible Debt. In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the “Convertible Notes”). The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company’s condensed consolidated balance sheets.
In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes. In September 2020, the Company issued 9,332,471 shares of the Company’s common stock and paid $44.0 million in cash, which included $1.1 million of accrued interest, to exchange $67.1 million aggregate principal amount of such Convertible Notes. The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments. As a result, a debt extinguishment gain of $8.4 million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. As of September 30, 2020, the carrying value of the remaining Convertible Notes was $20.0 million.
In October 2020, the Company issued 1,036,484 shares of the Company’s common stock and paid $6.0 million in cash, which included $0.2 million of accrued interest, to exchange an additional $8.8 million aggregate principal amount of such Convertible Notes. As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet.
The remaining Convertible Notes are governed by an indenture (the “Indenture”), dated as of November 26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee. The Convertible Notes bear interest at a rate of 5.25% per year, payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2015. The Convertible Notes mature on December 1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.
Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.
If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs. The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes. As of September 30, 2020, the balance of unamortized debt issuance costs was $0.13 million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets.
The fair value of the remaining Convertible Notes was $15.4 million as of September 30, 2020 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.
Mortgage Loan.  In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the “Property”). The loan agreement provided for a $12.9 million mortgage on the Property and had a two-year term with a 10-year amortization. The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3 million, which was paid in full in August 2020. At December 31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0 million and is included in current portion of long-term debt. The fair value of the loan agreement approximated its carrying value.  The fair value of the loan agreement was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate.

BioPharma Term Loan.  In December 2017, Lexicon entered into a loan agreement with BioPharma under which $150.0 million was funded in December 2017 (the “BioPharma Term Loan”). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly.

The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets. The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020. The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6 million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

The Company’s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas. The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions,
investments, transactions with affiliates and subordinated debt. If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.

In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs. The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method. The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.
At December 31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value. The fair value of the BioPharma Term Loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company’s estimated current incremental borrowing rate.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure Commitments and Contingencies
 
Legal Proceedings.  On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division. The Company’s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020. The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020. The lawsuit purports to be a class action brought on behalf of purchasers of the Company’s securities during the period from March 11, 2016 through July 29, 2019. The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes. The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.

Sanofi Arbitration. On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (“Sanofi”) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the “Termination Agreement”). In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement. The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement. The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys’ fees and costs.
In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and License Agreements
 9 Months Ended
Sep. 30, 2020
Collaboration and License Agreements [Abstract]  
Collaborative Arrangement Disclosure Collaboration and License Agreements
 
Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.
Ipsen. In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the “Ipsen Agreement”), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the “Licensed Territory”). The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.
Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory. Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan. Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO. Lexicon was responsible for the costs of all clinical
trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials. Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September 30, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen’s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen’s first commercial sale in Germany, a $3.8 million milestone upon Ipsen’s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen’s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen’s first commercial sale in Canada. In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6 million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of €72 million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained. Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO. Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen’s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.
The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5 million upfront payments:
•The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;
•The development services Lexicon was performing for XERMELO;
•The obligation to participate in committees which governed the development of XERMELO until commercialization; and
•The obligation to supply commercial supply of XERMELO under a commercial supply agreement.

The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights. In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon. As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations. The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement. The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.
The Company determined that the commercial supply agreement was a contingent deliverable at its onset. There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement. The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.
The Company determined that the initial transaction price was the $24.5 million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement. There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product. As such, the Company did not include those payments in the transaction price. The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation. The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate. The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate. The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development. The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services.
As a result of the allocation, the Company recognized $21.2 million of the $24.5 million in upfront payments for the license in 2014, and an additional $1.4 million in 2015 upon entering into the amendment. The Company recognized the $1.7 million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1 million allocated to the committee participation performance obligation ratably over the period of performance. Milestone payments that were contingent upon the achievement of a substantive milestone were
deemed constrained. If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated. Revenue recognized under the Ipsen Agreement was $0.3 million and $3.5 million for the nine months ended September 30, 2020 and 2019, respectively. Royalty revenue of $0.3 million was recognized for each of the nine months ended September 30, 2020 and 2019, respectively.
Sanofi. In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the “Sanofi Agreement”), with Sanofi for the worldwide development of Lexicon’s diabetes drug candidate sotagliflozin. In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.
Effective as of September 9, 2019 (the “Settlement Date”), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.
Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. See Note 7, Commitments and Contingencies, for additional information. In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019. Revenue recognized under the Sanofi Agreement was $286.0 million for the nine months ended September 30, 2019.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Impairment Loss on Buildings
 9 Months Ended
Sep. 30, 2020
Text Block [Abstract]  
Asset Impairment Charges Impairment Loss on Buildings In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $11.9 million. The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion. The property did not meet the criteria for classification as held for sale at September 30, 2020. Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $1.6 million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Earnings (Loss) Per ShareThe following is a summary of Lexicon’s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.
(in thousands, except per share data)Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator:
Net income (loss)$82,603 $226,086 $(53,079)$181,271 
  Add interest on Convertible Notes1,258 1,277 — 3,790 
Adjusted net income (loss)$83,861 $227,363 $(53,079)$185,061 
Denominator:
Shares used in computing net income (loss) per common share, basic107,309 106,272 106,974 106,200 
Add effect of potential dilutive securities:
  Share based compensation awards51 3 — 177 
  Convertible Notes10,192 10,365 — 10,365 
Shares used in computing net income (loss) per common share, diluted117,552 116,640 106,974 116,742 
Net income (loss) per share - basic$0.77 $2.13 $(0.50)$1.71 
Net income (loss) per share - diluted$0.71 $1.95 $(0.50)$1.59 

For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share. The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 11,773 and 10,576, respectively, for the three months ended September 30, 2020 and 2019, and 11,859 and 8,452, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block] The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block] Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Short-Term Investments: Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.  As of September 30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities. As of December 31, 2019, short-term investments consisted of U.S. treasury bills. The Company’s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.  The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.  Unrealized gains and losses on such securities are reported as a separate component of stockholders’ equity.  Net realized gains and losses, interest and dividends are included in interest income.  The cost of securities sold is based on the specific identification method.
Accounts Receivable [Policy Text Block] Accounts Receivable:  Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.
Inventory, Policy [Policy Text Block] Inventory: Inventory was comprised of supplies of XERMELO supporting the Company’s commercialization of the product in the United States. Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method. As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively.
Revenue [Policy Text Block]
Revenue Recognition:

Product Revenues

Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (“Ipsen”). Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer. The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. The Company’s net product revenues reflected the Company’s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts. Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company’s customers and such costs were included in cost of sales.
  
Collaborative Agreements

Revenues under collaborative agreements include both license revenue and contract research revenue. The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.

At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price. Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.

In agreements in which a license to the Company’s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.

For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related
sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).The Company may receive payments from its licensees based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.
Cost of Goods and Service [Policy Text Block] Cost of Sales: Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. For the three and nine months ended September 30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September 30, 2019, includes $0.4 million and $1.3 million, respectively.
Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.  Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred. Substantial portions of the Company’s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company’s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits. The Company’s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.
Share-based Payment Arrangement [Policy Text Block]
Stock-Based Compensation:  The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.  Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis. Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.  
 
The fair value of stock options is estimated at the date of grant using the Black-Scholes method.  The Black-Scholes option-pricing model requires the input of subjective assumptions.  Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.  For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price.
Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Equity Incentive Awards (Tables)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]    
Schedule of Accrued Liabilities Accrued liabilities: Accrued liabilities consisted of the following:
As of September 30,As of December 31,
20202019
(in thousands)
Accrued research and development services$50,217 $29,033 
Accrued compensation and benefits6,023 9,644 
Short term lease liability553 553 
Other1,704 2,921 
Accrued liabilities$58,497 $42,151 
  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]  
 Expected VolatilityRisk-free Interest RateExpected TermDividend
Rate
September 30, 2020:    
Employees91 %1.3 %4— %
Officers and non-employee directors78 %1.4 %8— %
September 30, 2019:
Employees88 %2.2 %4— %
Officers and non-employee directors78 %2.6 %8— %
Share-based Payment Arrangement, Option, Activity [Table Text Block]  
 OptionsWeighted Average Exercise Price
 (in thousands) 
Outstanding at December 31, 20197,695 $8.95 
Granted3,445 3.25 
Expired(236)12.91 
Forfeited (1)(1,909)5.71 
Outstanding at September 30, 20208,995 7.35 
Exercisable at September 30, 20205,108 $9.63 
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]  
 SharesWeighted Average Grant Date
Fair Value
 (in thousands) 
Outstanding at December 31, 20192,830 $6.35 
Granted3,144 3.27 
Vested(1,219)6.56 
Forfeited (1)(1,892)4.13 
Outstanding at September 30, 20202,863 $4.35 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Cash and Cash Equivalents and Investments (Tables)
 9 Months Ended
Sep. 30, 2020
Cash and Cash Equivalents and Investments [Abstract]  
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]
 As of September 30, 2020
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
 (in thousands)
Cash and cash equivalents$52,251 $— $— $52,251 
Securities maturing within one year:    
U.S. treasury securities38,796 40 — 38,836 
Corporate debt securities20,364 1 (6)20,359 
Total short-term investments$59,160 $41 $(6)$59,195 
Total cash and cash equivalents and investments$111,411 $41 $(6)$111,446 
 As of December 31, 2019
 Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands) 
Cash and cash equivalents$36,112 $— $— $36,112 
Securities maturing within one year:    
U.S. treasury securities235,463 94 (10)235,547 
Total short-term investments$235,463 $94 $(10)$235,547 
Total cash and cash equivalents and investments
$271,575 $94 $(10)$271,659 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Measurements [Abstract]  
Fair Value, by Balance Sheet Grouping [Table Text Block]
 Assets and Liabilities at Fair Value as of September 30, 2020
 Level 1Level 2Level 3Total
(in thousands)
Assets
Cash and cash equivalents$52,251 $— $— $52,251 
Short-term investments38,836 20,359 — 59,195 
Total cash and cash equivalents and investments$91,087 $20,359 $— $111,446 

 Assets and Liabilities at Fair Value as of December 31, 2019
 Level 1Level 2Level 3Total
 (in thousands)
Assets
Cash and cash equivalents$36,112 $— $— $36,112 
Short-term investments235,547 — — 235,547 
Total cash and cash equivalents and investments$271,659 $— $— $271,659 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The following is a summary of Lexicon’s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.
(in thousands, except per share data)Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Numerator:
Net income (loss)$82,603 $226,086 $(53,079)$181,271 
  Add interest on Convertible Notes1,258 1,277 — 3,790 
Adjusted net income (loss)$83,861 $227,363 $(53,079)$185,061 
Denominator:
Shares used in computing net income (loss) per common share, basic107,309 106,272 106,974 106,200 
Add effect of potential dilutive securities:
  Share based compensation awards51 3 — 177 
  Convertible Notes10,192 10,365 — 10,365 
Shares used in computing net income (loss) per common share, diluted117,552 116,640 106,974 116,742 
Net income (loss) per share - basic$0.77 $2.13 $(0.50)$1.71 
Net income (loss) per share - diluted$0.71 $1.95 $(0.50)$1.59 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Inventory (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Inventory [Line Items]          
Inventory, Raw Materials, Gross         $ 3,200,000
Inventory, Finished Goods, Gross         900,000
Inventory, Work in Process, Gross         $ 200,000
Amortization of Intangible Assets $ 300,000 $ 400,000 $ 1,200,000 $ 1,300,000  
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees 91.00% 88.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee 1.30% 2.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees 4 years 4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees 0.00% 0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors 78.00% 78.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors 1.40% 2.60%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors 8 years 8 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors 0.00% 0.00%
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares
shares in Thousands
 9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 8,995 7,695
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 7.35 $ 8.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3,445  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 3.25  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 236  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price $ 12.91  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 1,909  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price $ 5.71  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 5,108  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 9.63  
Restricted Stock Units (RSUs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2,863 2,830
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 4.35 $ 6.35
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3,144  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 3.27  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 1,219  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 6.56  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 1,892  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value $ 4.13  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Accrued Liabilities [Line Items]    
Accrued research and development services current $ 50,217 $ 29,033
Accrued compensation and benefits current 6,023 9,644
Operating Lease, Liability, Current 553 553
Other Accrued Liabilities, Current 1,704 2,921
Accrued Liabilities $ 58,497 $ 42,151
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Mar. 31, 2017
Accounting Policies [Abstract]              
Intangible Assets, Net (Excluding Goodwill) $ 0     $ 0   $ 19,716 $ 24,700
Asset Impairment Charges 0 $ 1,600 $ 28,638 0 $ 28,638    
Intangible Assets, Net (Including Goodwill) $ 18,500     $ 18,500      
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Asset Sale (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2020
Asset Retirement Obligation Disclosure [Abstract]            
Gain on sale of non-financial assets $ 132,800 $ 132,818 $ 0 $ 132,818 $ 0  
Proceeds from Sale of Productive Assets $ 160,385       0  
TerSera Maximum Development, Regulatory and Commercial Milestones       65,000    
Xermelo Pretax Net Loss   (2,100) (4,100) (12,100) (10,800)  
Severance Costs       5,500    
Debt Instrument [Line Items]            
Gain (Loss) on Extinguishment of Debt   $ (255) $ 0 (255) $ 0  
Severance Costs       5,500    
R&D severance costs [Member]            
Asset Retirement Obligation Disclosure [Abstract]            
Severance Costs       2,500    
Debt Instrument [Line Items]            
Severance Costs       2,500    
SG&A severance costs [Member]            
Asset Retirement Obligation Disclosure [Abstract]            
Severance Costs       3,000    
Debt Instrument [Line Items]            
Severance Costs       3,000    
Forecast [Member]            
Asset Retirement Obligation Disclosure [Abstract]            
Severance Costs           $ 5,700
Debt Instrument [Line Items]            
Severance Costs           $ 5,700
BioPharma [Member]            
Debt Instrument [Line Items]            
Gain (Loss) on Extinguishment of Debt       $ 8,600    
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Cash and Cash Equivalents and Investments (Details 1) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Cash and Cash Equivalents      
Fair Value      
Amortized Cost $ 52,251 $ 36,112  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses 0 0  
Estimated Fair Value 52,251 36,112  
U.S. Treasury Securities      
Fair Value      
Amortized Cost 38,796 235,463  
Gross Unrealized Gains 40 94  
Gross Unrealized Losses 0 (10)  
Estimated Fair Value 38,836 235,547  
Total Short-term Investments      
Fair Value      
Amortized Cost 59,160 235,463  
Gross Unrealized Gains 41 94  
Gross Unrealized Losses (6) (10)  
Estimated Fair Value 59,195 235,547  
Total Cash and Cash Equivalents and Investments      
Fair Value      
Amortized Cost 111,411 271,575  
Gross Unrealized Gains 41 94  
Gross Unrealized Losses (6) (10)  
Estimated Fair Value 111,446 $ 271,659  
Corporate Debt Securities      
Fair Value      
Amortized Cost 20,364    
Gross Unrealized Gains     $ 1
Gross Unrealized Losses 6    
Estimated Fair Value $ 20,359    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Cash and Cash Equivalents and Investments (Details 2) - USD ($)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Schedule of Investments [Line Items]    
Realized Investment Gains (Losses) $ 0 $ 0
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Details 1) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Fair Value    
Cash and Cash Equivalents $ 52,251 $ 36,112
Short-term Investments 59,195 235,547
Total Cash and Cash Equivalents and Investments 111,446 271,659
Fair Value, Level 1    
Fair Value    
Cash and Cash Equivalents 52,251 36,112
Short-term Investments 38,836 235,547
Total Cash and Cash Equivalents and Investments 91,087 271,659
Fair Value, Level 2    
Fair Value    
Cash and Cash Equivalents 0 0
Short-term Investments 20,359 0
Total Cash and Cash Equivalents and Investments 20,359 0
Fair Value, Level 3    
Fair Value    
Cash and Cash Equivalents 0 0
Short-term Investments 0 0
Total Cash and Cash Equivalents and Investments $ 0 $ 0
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Debt Obligations (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended
Nov. 30, 2014
USD ($)
Oct. 01, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Sep. 28, 2020
USD ($)
shares
Sep. 30, 2019
shares
Aug. 30, 2018
USD ($)
Dec. 18, 2017
USD ($)
Nov. 20, 2014
$ / shares
Debt Instrument [Line Items]                
Debt Issuance Costs, Gross             $ 4,100  
Proceeds from Convertible Debt $ 87,500              
Conv Debt Instrument Interest Rate Stated Percentage               5.25%
Debt Instrument, Convertible, Conversion Ratio 118.4553              
Debt Instrument, Convertible, Conversion Price | $ / shares               $ 8.442
Debt Issuance Cost $ 3,400              
Unamortized Debt Issuance Expense     $ 130          
Debt Instrument, Fair Value Disclosure     15,400          
Mortgage Debt Instrument_Revere_LXRX     $ 11,000     $ 12,900    
Mortgage Debt Interest Rate_Base_Revere_LXRX           5.50%    
Mortgage Debt Interest Rate BasePlus_Revere_LXRX           7.50%    
Mortgage Debt Balloon Payment_LXRX           $ 10,300    
Debt Instrument, Interest Rate, Stated Percentage     9.00%          
Debt Instrument, Face Amount             $ 150,000  
Common stock, shares issued | shares     117,231,000   106,679,000      
Convertible debt exchange     $ 8,400          
accrued interest on convertible       $ 1,100        
Convertible debt exchange Remaining Notes     $ 20,000          
Convertible debt exchange - Total Principal Amount       75,800        
Convertible debt exchange - September principal amount       (67,100)        
Convertible debt exchange- September cash portion       $ 44,000        
Convertible debt exchange - September share payment | shares       9,332,471        
Subsequent Event [Member]                
Debt Instrument [Line Items]                
accrued interest on convertible   $ 200            
Future Convertible debt exchange shares | shares   1,036,484            
future convertible debt exchange   $ 6,000            
principal amount of convertible notes   $ (8,800)            
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]      
Sanofi termination cash payment $ 208,000 $ 26,000 $ 208,000
Other Commitments [Line Items]      
Sanofi termination cash payment $ 208,000 26,000 $ 208,000
Accounts Receivable [Member]      
Commitments and Contingencies Disclosure [Abstract]      
Sanofi termination cash payment   23,200  
Other Commitments [Line Items]      
Sanofi termination cash payment   $ 23,200  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and License Agreements (Details)
$ in Thousands, € in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2019
USD ($)
Nov. 30, 2017
USD ($)
Oct. 31, 2017
USD ($)
Mar. 31, 2015
USD ($)
Oct. 31, 2014
USD ($)
Oct. 31, 2014
EUR (€)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Collaboration and License Agreements [Abstract]                            
Sanofi termination cash payment             $ 208,000       $ 26,000 $ 208,000    
Sanofi Revenue Recognized                     286,000 286,000    
Ipsen Total Payments             47,200       47,200      
Ipsen Maximum Regulatory And Commercial Milestones                     9,600      
Ipsen Maximum Sales Milestones | €           € 72                
Ipsen Total Upfront Payments       $ 24,500                    
Ipsen Milestone Payment                   $ 6,400        
Ipsen Milestone Payment Received $ 2,300 $ 3,800 $ 3,800         $ 1,300 $ 5,100          
Ipsen Revenue Allocated to License Deliverable                         $ 1,400 $ 21,200
Ipsen Revenue Allocated to Development Deliverable         $ 1,700                  
Ipsen Revenue Allocated to Committee Deliverable         $ 100                  
Ipsen Revenue Recognized                     300 $ 3,500    
lxrx_sanofi initial cash payment             $ 26,000       26,000      
Ipsen Royalty Income_LXRX                     $ 300      
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Impairment Loss on Buildings (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Text Block [Abstract]  
asset sale price $ 11,900
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Share [Abstract]            
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 51     3 0 177
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 10,192     10,365 0 10,365
Weighted Average Number of Shares Outstanding, Diluted 117,552     116,640 106,974 116,742
Net income (loss) per common share, Basic $ 0.77     $ 2.13 $ (0.50) $ 1.71
Earnings Per Share, Diluted $ 0.71     $ 1.95 $ (0.50) $ 1.59
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 11,773     10,576 11,859 8,452
Net Income (Loss) Attributable to Parent $ 82,603 $ (69,071) $ (66,611) $ 226,086 $ (53,079) $ 181,271
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities 1,258     1,277 0 3,790
Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted $ 83,861     $ 227,363 $ (53,079) $ 185,061
Shares used in computing net loss per common share, Basic 107,309     106,272 106,974 106,200
XML 49 R9999.htm IDEA: XBRL DOCUMENT v3.20.2
Label Element Value
Liabilities assumed by TerSera lxrx_LiabilitiesAssumedByTerSera $ 3,180,000
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�>UH%=8!R76P:_!^MTL72KZ[(EPM12#JV?" RH(F'(:D#82\DJ'=7R6 M^Y:$9M#(\CV__FEG9%@R,GPW1GY7&=(L.5/"*5.O;M6>J%8YM?@O")696I#: MF!@VE'8]KT/I48EK=# NL3^P/?0>-:1T+=2!TB]1^N^FWM7SBG*374/:!L1O MR(7<03L.Z%1;HO-^>K5"V4NTHNJZ:A!9/NR 6W, \-V$J\VN[<(5-=65@[[3 ML8! 5&%![R==*YC]I$,-Z?K6L$NYRC' W2W#X5/.@,#SF&S;+HN*ZKKUH3/J M0%(9$>C]&B3[B.4UQ/*M@>O4/EW*53X';C7CTC?[J9T;E"[A.%8]9/JN_R8AP(".<5F/AEJ5/ MBFH2;AW3S4T?C0;N&_O3&N4Z'2.A\@;P<'/PGW/1F!7&50#U#Y* +YAR\(#C MK'UR-*V#U[2*+5&#>M1KKBJ' 8]N,7;DZJW+:J6B:3Y1IT=$^S(QF%O?M'T9N.!XY\U(&ST IC3Q/Q4LGQ:G@*?F;-/NPK/CY!O,%]2]:\I)@N5 MZEA#)0'/3V7S&\E6YF!SSJ1DB;F," X)UP'J_8(QN;G1'91GXY._ 5!+ P04 M " !IA%Y1*?1I4K<" !F!P &0 'AL+W=O6XK22M!J&A)H%1W;BVDOW/326"1V9CLM M?/N=G1"5/F2\26SG_G>_N]CG9"ODB\H!-'DM"Z[&3JYU=>.Z*LVAI.I*5,#Q M2R9D235.Y=I5E02ZLJ*R< //&[@E9=R9)'9M+B>)J'7!.,PE47594OEV!X78 MCAW?>5]X8NMO]K< M,9%S-R?G9!S@CCY$)T%0JZ"@767WC"W[&T?S^@$;G7 M4*H_/2'"+D1H0T3_"2%! 95I3K!PN!,8J/#&:*) ;EF+@M)82%XX5M0DQ ML"',V=U,8B_PAXF[V:W=H54P\L*PL_K 'W7\T:?X4U%B=U&T.:"8PQ(X9$SW MNXQVB@1>$>]B'1J-!%!VGCCOJN)?Z>P62VBW^ -@(+KL__'9)IJ=YXP.4 M.-['[;?Y0#OH: ?]M#H'>>P,]L(.#D#\H1?MT1X:!:/ /XX[['"'G]H2.Z#' M^(:'F_8Z&NUOVD.K*/#C?4)WIPN:&^B1RC7CBA20HFUWM4[^ 5!+ P04 " !IA%Y1N#N)(0$# M #A"0 &0 'AL+W=O]W MLF-W-XR_B 0A"=Y20D7/2J3,.K8MP@2E4-RQ#%'U9LUX"J4:\M@6&4I9K;2>><)Q(/6'WNQF, MT1+)YVS!UA,5HR]Z,$\ZEF. M#@@1%$JM -7?*QHA0K20"N-/J6E5+C6X^[Q5GYK<52XK*-"(D9\XDDG/:EL@ M0FN8$_G$-C-4YN-KO9 187[!IK1U+!#F0K*TA%4$*:;%/WPKZ[ #*)WC@%<" MWC[0/ $T2J!Q*= L@>:E(?DEX%_J(2B!X%*@50*M2X%V";1-=XMVF%Z.H83] M+F<;P+6U4M,/9D$86K404[UTEY*KMUAQLK\LEBQ@:[#$,<5K'$(JP2 ,64XE MIC%8,()#C 284PEIC%<$@8$02 IP/4828B)NP!?PO!R#ZZL;< 4P!=\3E@M( M(]&UI0I2N[+#,J!A$9!W(J &>&14)@),:(2B(_RDGK^OX6U5G*I"WK9"0Z]6 M<(FR.]!P;H'G>,Z1>$;U^->J\;G@IY_S_E"/CU&H!@A]R";^KT MN9Z\A22/M-\'QJ(-)N3FV,8HQ ,CKH^MNL\]:/!Q:N/&PO=V]R:W-H965TN&>KM3(#3K^WH2N8@OJ^N1/ZSBE8%BR"6#(>(P'+J\8 M7TY(UP!2B[\9;.7.-3*IS#C_86YN%E<-UT0$(3E54WG9J *MKO";Y%PEAK-G.1SF^*UC/"8M.* M4R7T4Z9QJC^04O?[E(: S@)0E(7R,SI'WZOP?%!&AU5>BO6>,AHB:B&J76<;JIZQF>WGLXR;IN+H, MC[O-4V^&.R_-@JK9'M'H.**QC>A%?;RB/IZU/G>"SP$6$BT%CS)=TE72HXLD MW;30X&")O&K(OMOL>'LA9V;>ZR'[11O(*8@*+JE3RQ*(A3 H][A-Z:C MONCN6B4A55S\0EI!T9!'$8ATKF]9"%K>8ZA+9N17HO0]UST0:;N(M&V-]%\0 MD0Y-EU,K_1/Z4W?_5R[K_ _;%?_G!.^W6U!CU:I8C6JL<)5L7&?F=@[EW"ER M[EASGNK9$'IY@:Z]K&V<4:?BV/,.N>T6;KM6;0E@IM!-K(4C2:7EX:LV0#<* M(FF3$>R6^[;[NI"G[;/1D]*18O$J87*?N])HQ$=1NN&YEG9P3;V^5!#56 M^].:FWA6HK&5Z&7N.^\L^-0YS1F.FU1,2L_$ZOG^-QIM?@^0+"*8FPC0PRU$ M,Q#6J2VW)?QQ^Q(N-R9LWYF.*6JK4E1RN*BEY&/O7=9**=#8KM#'I%857$MJ MI>!BN^).)VG##-[4,*7$X<['-4RI<+A[F(J)'=4@I(<0N(6^M6*D6Q*X6;WU? M&>6\NW7L^)4Z.CM'(/H->Y6>;DDMMDFLLB_"8K0X01NDYT9[XT-\&>":\1&^ M'&?G8R5]=EQW2\6*Q1*%L-2NW(NV[DV1G8!E-XIOT@.8&5>*1^GE&N@"A#'0 MSY>5;PJ;,58O?&=?EJ2W+,1W1'"OEE0UF.A1RR1Y?O&,%KE91G+O*\R,UQ6CBS MB7IWRV83NA=96I!;!O@^SS'[\XYD]#AUH//TXEOZN!7E"W%'LB3B?G?+ MY,AM4-9I3@J>T@(PLIDZ;^&;A:\25,3WE!QYZQF42WF@]&.E[)B&1D M)4H(+'\.9$ZRK$22/'[5H$XS9YG8?GY"_Z 6+Q?S@#F9T^Q'NA;;J3-VP)IL M\#X3W^CQ$ZD7%)9X*YIQ]1<E8/)K M*O/$;([Y%N!B#=3#^U_[]( S4@BN7GXN#H2+7(U?+HC :<8!? 5NP/UR 5Z^ M> 5>@+0 =UNZYS*>3UPA.97([JJ>_UTU/^J9?TEV(^![KP'RD->1/K>G+\A* MIL,R'28=Z8O!LY^GN[*033514TVD\()+JVG!]AML7V'[/=@?<,K =YSMB04L M:, "*]&W.64B_4LD4\I%5]NJ_$CEE^9QF(4(A7#B'MK=,:/\"$+41)V0"QMR MH97<1T8Y!_>%]+%,*$7-20BRXC]T6.22>[Z+_L M;!$G[.*&76QE]YZ+5)JAI-6W72IJL3%Q5W?-*$MWQPW%L97B_6@Y G>R?'S/ M_H E6>U9*M+S"IY )PUT\GR)0$];H_=,D=0 )Q4:QTET5L>.,.2'0>1W5Q*V MS!M>22DU4)M"<+X;.V*2H(>B=D1HM\0+]%(CV033$7(#>S0#M;-"_RJJJ6%. MVSWVC7:;8;+=81#W\-2F#>VN?4<%SL!R*[?EC2 L;_]_MNUX;;PPO(* M%5" MNU<.$)#I@&$"(Z/M9IA50-HNH=TO+Q"0:8;!N5]VQ/0*2-LEM/OE)0(:F^HP M-F='3*^"M/'"Y#H*2KKZG83G),TPFX*0MG1DM_1*08,/O;8CH39I!)\O*M0Z M8MH-]?^B0J9)0@@#>+Y=.^)0#,,X[*FR]E-D]]/AJD*F51JJZHCI4Q725HKL M5GJ!JFHDJZJZ8OI4A;0=(_M!>*BJD'G*+1L>&"Q#X[@N&QZ%20]1;?3(;O1S MRG:42:9@01[$L$,=TB:-XBL(2!LJLAOJ &9'HD\/^K;=-HED=TE!^MB40.U M.P6[9_>U]_EV[[M@R_OF@37JF5[;H&\_JP[=S#5,=%I\8X^ZK3N/\H;J*V:/ MLI@@(QN9YXUB29Y5ES[50-"=N@9YH$+07#UN"5X35@;([QM*Q=.@O%EIKMYF M_P!02P,$% @ :81>43G=9K X @ ( 4 !D !X;"]W;W)K&ULC51M;]HP$/XK5K0/K;21D#"V5A"IT&Y#:B4$ZO9AV@>3 M7(A5OZ2V ]U^_;)7^LF4 ):\""[--"BMK:[#T&0E M"&H&J@*))X72@EI4]38TE0::>Y#@81Q%XU!0)H-TXFU+G4Y4;3F3L-3$U$)0 M_7L&7.VGP3 X&%9L6UIG"--)1;>P!OM8+35J8<>2,P'2,"6)AF(:W ROYR/G M[QV^,]B;GDQ<)1NEGIRRR*=!Y!("#IEU#!1_.Y@#YXX(TWAN.8,NI /VY0/[ M%U\[UK*A!N:*_V"Y+:?!YX#D4-":VY7:?X.VGH^.+U/<^"_9-[[C44"RVE@E M6C!F()AL_O2E[4,/@#S' 7$+B-\"3D5(6D#B"VTR\V7=4DO3B59[HITWLCG! M]\:CL1HFW1375N,I0YQ-Y]24A,J<>.'NN68[RD%:XXT+N0-CA=AQ20<59BU 6=-P/A$P"ORH*0M#;F3.>2O\2$FWU40'RJ8 MQ6<)UU -2!*])W$41T?RF?\W?'AU)IVD:VCB^9)3?+AG>HR-9 M6!#FUYDPHR[,R(<9G0BS LK9'^B/B'S%I<4YW2MCP!P=3<,Y]IQNOW_V=9_-,W;\4#UUI7" MH4#*:/ )ET%4O:@N #=HYC^!5!+ P04 M " !IA%Y1X-%<02T# #-#0 &0 'AL+W=OE^XCU>1U OV>+C&*S(C\G%]Q]7,+ED6<4)2$;,4<;(<6=_A\D-'(&EAH099X0^4]V_TD14*^YILS*K)/M,MC [7C M?",D2PJPFB=QFG_CMZ(0-0#TC@#< N#^*\ K %Z6:*XL2VN*)1X/.=LAKJ,5 MFQYDMHC81N!T(8:V5 HTCSTO=KO*=W./[#8CZPOD.>?(=5RG M!3XQPZ=DKN"@X1#NPVV5=YF\6R;O9GS>A\D;R+R2S,O(>D?()EA$2)4%98,? MKYMXBZFN95N9J;-GU#F+&)?? M).$)NDFW1,CDF,BR@V0LM#=N,,C1L6.H,.VK8L+G]8. =OO!FE*EAP:FL:&@TJGX4.C!8JIX4.K;;@JA?+.:RG*61?8^6RT)7- M0HN#.E[M918BFV''1%8F"U_NLM#BGVWJFV''U%<6"Y_U6,_47I7)0@BK]+F^=TAGTBVSH[?STRJPWPVC-1]BW =H)XO&9/O M$WVB+V]PX[]02P,$% @ :81>47@$Y >D!0 C1< !D !X;"]W;W)K M&ULM5CQ;YLX&/U7K&@G;5(;L(% IC12F[1KI76+ MTG4WZ72:'.(D:&!GMFF[T_[XLX$"2;";2G>_M$#XGI^_[_-[QJ-'QG^(#2$2 M/&4I%6>]C93;]XXCX@W)L.BS+:'JEQ7C&9;JEJ\=L>4$+XN@+'60ZPZ<#">T M-QX5SV9\/&*Y3!-*9AR(/,LP_W5!4O9XUH.]YP?S9+V1^H$S'FWQFMP1>;^= M<77GU"C+)"-4)(P"3E9GO7/X_L8K HHWOB;D4;2N@9[*@K$?^N9F>=9S-2.2 MDEAJ"*S^/9 )25.-I'C\K$![]9@ZL'W]C'Y53%Y-9H$%F;#TSV0I-V>]J >6 M9(7S5,[9XS6I)A1HO)BEHO@+'LMW!UX/Q+F0+*N"%8,LH>5__%0EHA6 H"$ M50%H/R T!'A5@'=L@%\%^,<&!%5 L!_@&@(&5<#@V$F'54!X;$!4!43[ ;XA M8%@%#(MV*.M7%'^*)1Z/.'L$7+^MT/1%T4%%M*IY0G6SWTFN?DU4G!Q/R4*" MSXLT66/=? *\G1*)DU2\ V^ \0&"2+LER-]Y1W.L)H.<)7" KX"?VT >>>P*0"_W[ MNREX^^9=!ZV)'>5S+/O A1H%N15*.?<.K*D=ZXYLGQF]C'5Y!!:*CL.Z.IH7 M'!I!/MA!SO-U#1*9TWUM1YF2N ]@,2T8FE%NCB@]JDK?=*NEJ;QZ57@%LF=; M%3=42)XK89?@KX_J!7 C22;^ML#[-;Q?P/M6>"%R3&,")DSHE?6!,]%5D.L2 M:U!@:>]Z&/O0=4?.0P>#H&806!G,.(L)60JPXBQ3#.@#X3)9I 1H;EW+.CA@ M$86!B<:@IC&PTM #@_UDWU!)5!DEF&-)P)U4?Y=@1GBL?E3^V]4G]E&"/@K^ ML)0MK-F&1Y2M)GK2SMOS3;$)F&LM[4IBB3]L)1'"J.\'@=>=QZAF%OTWS&8\ M41WW&YA62YG.N^[Z-NCL.:X_"53=^5H>%!FWF^J@T-C;0;B8;>JVBW1./[A=K^OD#_PPOP03]P;:(!&[&'=K6W$ 6:Z"S-Q8MD M[4.$+Y%M? ':C6&7[ 5.4Z9E _\J.L)([] =H.L9:]S8 [0K]\%BVR5'F M,'UAC&'?M>>NL0?X2G^XPDIASC.6TRZMNZ[@=K*F+-68ML8-H-T.)BS+5-74 MQT/\XZ3>PRO)4[GZ;=;]:06[HS P1-[AJK[J>M4=#,*AF7YC%-#N%.WMR%+G ME#S%&TP-U3UTC,@HBJAQ#&1W#!S'7*6XXE<^XX=6YD^_P"^-$&@>R& M8#D)S51M30';%-E)L M,XRQV("MWK@PVLFNX]/ -U>W,0%D-X'C\E?H"-B6UF#3ESB?92+8M#@873$J6 M%9<;@I>$ZQ?4[RNF)E/=Z 'J$_CQOU!+ P04 " !IA%Y1/"J@X0 M-O+5AA:UD4JZ:4A#0W1L#V@/;G+;6,1V9KLM_/O93AH"M"G:V%Y:V[GG7)]S MG5R/-ES5:0X4RQ-> M-/%EQ0K/14+%U9"L"9!='" M#3PO%6H:[[Y#+6@ON%+>2'M+]I4L5'?0>E**DYKL-X!):SZQ_>U$2V OP\0U(#@ MM8"P!H3/ ;T]@%X-Z%EG*BG6ARE6.!X)OD'"1&LV,[!F6K263YBI^TP)_91H MG(H33BE1NI!*(LPRE'"F"%L"2PE(=#0%A4DAC]$'=#.;HJ-WQ^@=(@Q]R_E* MZG@YA>%RTSKC>94QV),Q1)= MA#,H3U#HO4>!%WB[]O-W\.FKX?ZP0TW8%#2T?.$?%71*9%IPN1* ;B=SJ81^ M[WYV9.TU67LV:V^?"LSX@B %0I]1;-_H%,LOE5Y2!0V]';+SH$72B@LLNVJ$D0O;5M MT>MLJ\+Z!VP[2/9$U6FCZK13U21-^%_JT70*=@^@R;=#0#_[C M"1\V68=O7*ID^+(&8;#/7-][_&)[_^94^JVFX+^UV)HQ.J#6;;4J"F)I6[Y$ M]L!4G^QFM;E63&PS?;:>F.N&;8&/--5=Y1*+)6$2%;#0E-[)J:Z J-I_-5&\ MM UQSI5NKW:8ZRL3"!.@GR\X5]N)2=!&PO=V]R:W-H965TF99/%SC&/%3FN)$_K.D+$9" M-MG*XBG#:)&!8F(YMNU9,8J2SG"0]3VPX8!N!(D2_, W\0Q8J\7F-#M>0=V MRHY9M%H+U6$-!RE:X45Y9P3/[J&O )G%;Q'> M\KUWH*8RI_2;:MPNSCNV4H0)#H6B0/+QC"\Q(8I)ZOBK(.U48RK@_GO)?IU- M7DYFCCB^I.3W:"'6YYV@ Q9XB39$S.CV!A<3ZBF^D!*>_8)M;NO['1!NN*!Q M 98*XBC)G^BE<,0>P($- *< .*8 MP"XIH!N >B: GH%H&<*\ J 9PKP"X!O M"@@*0& *Z!> OBD VF7D;&-(%6SC:,,RW- XWK ,.#2.."Q##HUC#LN@YPO> MRE=\MEW&2*#A@-$M8,I>\JF7;,]E>+E+HD0=#X^"R7\CB1-#N:T(FE.&\LV: M+, D"N7NQV"T8AC+@T!P<#+& D6$OP?O0)2 7]=TPZ4I_P!^_BEPO>XOJG<: M$2(Y^, 24I=BM\)"PT6NP6G0 ,&4)F+-P56RP L-_J8=[Q[#3]KQ_6/XNR/Z MG18"2P:DBHI31N7":66\QO-3X 0?@&/#_M/C&)R\>Z_1==G.?3X%K9RQ^ M,\NXG>4^%)(%'F.Y:F>9(E:Q])I9KLVU=)M9/GX'R]73#)P4RUC'==/.]8C3 MTL>.W:SHMIUEC,-*44N\/YG[.&AF^6S.TA+OR?_BEZDQ2YM?[LR]ZS6SW)NS MZ%?PP59WJP/8S6C=_W( _S&:<\%D*?5GRXC=:L1N-F*WR:DHHR G]#)"57 ^#QT[L&U[8#WO+PF-F5>SFAXE.YA5KYI5SV16 M,_R,DPV6SY"NDNAO?3[(J7K[$@*-TJ-F!TJ]2JG7JO0VY5@F42H0 0^YSW5) M\\:KC=[UG9K/CUD=2/0KB;Z!Q"EZB>)-+'VYVA D*'L%([D^+VD<8Q9&4K[, M^5@6*0G636#BUZ3UO29E0:4L^ YECTB.OZ<"_%-6)+JLD#.K K(2Y#MZ.?U* M3M\XED_IDLDRH"VF5_WZVN_VFGP"[5T19YMXI?1#*4%W^!=,^Q*\;J."O3(2 M_H@"M0^Q_/[3[<*+@O+ &^[;!7ZIL7*#MU9C(ZM;C16LC?A)8]6#C2YR=BYR M#%Q4'E C0FB(!%X 0:LC?XR)=!9#8^7 QB,![A(5=']4 M_UAV$IIF$6^?PW4QR,$<_$9QNYP&VY-:BSAU7D5"X&/NO8;US-0<]EU>@NV) MZ5!9>UZ"]8Q36Y[3PNA@J3>?(;NL!-O3$GEA+U]YGD6C)!+J?#]6%Q241S+^ M!-:3E-.<1^$N2T&3-#6CKXB(5W";A#3&7R=?9E^TOO7K;JM)L/:^I&626V47 M5QR$=).(O!:I>JO+L5%V1?"F_P*>?82:_AMX]EG7/X%G4UW_G;I\R[[T=W+R MFSM9IZ^BA ."EU*:?>I+][+\,BQO")IFW_US*@2-L]&PO=V]R:W-H M965T2X^_:39,=DL.S%OI/N?O<_G91UQAZH0G3P5BM-"U8YU]QS M3D6%M:"):5#[G9VQM7#>M7M.C451QJ1:\31)[G@MI&9Y%M?6-L],ZY34N+9 M;5T+^WN)RG0+-F6GA6>YKUQ8X'G6B#UNT+TV:^L]/E)*6:,F:318W"W8P_1^ M.0OQ,>";Q([.; B=;(TY!.>I7+ D"$*%A0L$X7]'?$2E LC+^#4PV5@R))[; M)_JGV+OO92L('XWZ+DM7+=@'!B7N1*OMCY[<,BI:< MJ8=DKZ"6NO^+M^$%>^&C^G14GT;L[ +V M!=\<+)4I#O#C84O.^B'__ ]W-G)GD7M[@2N(_'L@H1 :*PO\5\,]X2X2PM4_ MYM/IQR3)^/&\,#\;3;CE7X7=2TV@<.?SDLG[.0/;WYS><::)T]H:YV44/K5%KC! $1( !D M !X;"]W;W)K&ULM5A;C^(V%/XK%IJ'76F&W$@" M(P:)VTRGZF[1TND^5'TPP8"UB4UM9YC]]SU.0@8(0F]9RN1#9Z?4_MYQ9+(C&99=OB<,WFRXR+""H=@ZKX MKALY&::L,QH6%X_ M=%QM$4E)HK0*#'^O9$K25&L"._ZJE';J-;7@Z?-1^V/A/#BSPI),>?J5KM7N MH=/OH#79X#Q57_CA)U(Y%&I]"4]E\8L.%=;MH"27BF>5,%B045;^X[>*B!,! MT&,7\"L!WQ3H71 (*H'@6H%>)="[5B"L!,)K?8@J@>C:%>)*("XVJV2WV)H9 M5G@T%/R A$:#-OU0[&\A#3M"F0[%I1+PEH*<&LVQ8)1M)5H0@98[+ CZ,",* MTU1^1'?H93E#'VX^HAOD(*G?2D09>F%4R=N3B=]V/)>8K6'RYFP\=!08J9=R MDLJ@26F0?\&@ 'WB3.TDFK,U65OD']OE!RWR#I!3,^0?&9KXK0J79-]%@7N+ M?-=W+?9,V\5_SEFK^*Q=_!,6(.Y=%)]?;;PWL)'YWWQ_^M>KGVU%4 =K4.@+ MK@_6/\8KJ004M#];]/=J_;U"?^^"_F>6" )U5N$437F60:E M1Z$W=%Y/][<)"XYX:B*\.*XQ9U2%-57A_T?5E+-7(HIN!J,962FT M)$DNJ*+$RE/8= BRC>HLJ&"*#3H:J),NGZDYXRPJ"8L:B7L:]$4(3;&X#HT M>?0YSU80QL?(D>C77$D%11,B_+9DS5K_)E'3/"\.0Y,-&RR*>H:SCQ:8&PWB MGL&)55O<\^VDQ#4I<2LIG^&L15G",^@Z*9?0;M$$2YK8>"A5 MQZ<;V3T)ZY*%)LCO>F8&-4%W;M>(FZU!X/6CT>,T77QXKPGO1H_I:D.31LM!$\TQ5E M#Q5$517"1M,XXSE3-I8&MOR(C3V?6U!N&$<&3S9=_1,.2J*:J'XOO) :GOM^ M,G-_F!S/57+\4B2'65H7P(2=@TIU=&J2'[D&"5,+["X:N&9,S:RX*/+,V+/@ M?%BV;])JTQ<&;FP2:\%Y?<^_E';>R:G7:^5VU@S!V[I!L;+F6,.N%BQ[F*)Z M*]J;5V7*61#Y8=^DSH8RR]FC!65V+PLDB ?N!<;\=\;\5L9>H#'),OP@2VMJ MCI&9ICS!^DT9EHHF= _YR[9G#+?4MFKYLX@-^E$CPIHPWX^#R"SI%IP]PIHX M2' WNA1A[T=5+VCEJVKJN3X.PHTH*2J:YH-!6NM>]T]:7;76>;6* W=@LF/# M17[LF^Q8<S]?>+<7%K-^8GWOW< ML\P_ZN\=Q87W77WYL00N2%O*)$K)!I:"?@C&BO+[0SE0?%]-P1 MO"9" ^#]AG-U'.@%ZJ] H[\!4$L#!!0 ( &F$7E'B:QL6RP$ /\# 9 M >&PO=V]R:W-H965TU^?U1SIH\VI; $?. M2G8VHZUS_0-CMFI!<7NC>^APIM%&<8>A.3#;&^!U@)1D<13=,<5%1_,TC.U, MGNJCDZ*#G2'VJ!0WERU(/61T0Z\#3^+0.C_ \K3G!]B#>^YW!B,VJ]1"06>% M[HB!)J./FX MB/'9J.8[86\"C6Y$YT]Q[PS."N1<_IV7(%/F4,H/L&K"MN]CGR7@4;HWP&($ MXQ7PA#'_+T/MZ M\FS.OQ>BCZ/F]K*N6(R*=T'1OY93GFSN(_Q2=EI:8XOC\4_C!S<'T5DBH4$R MNOEX2XD9K]L8.-V'K2^UP_,/W19?*!B?@/.-UNX:^$LPO_G\+U!+ P04 M" !IA%Y1RZ7J,%@" "^"P #0 'AL+W-T>6QE<#>YR4EBR3_!<4J[2YZ'I^))L.,T2;L&5;N M]J8^YSL^W_ELG]0.2KUF\) #:+3B3)0ASK4NWGM>&>? 27DA"Q FDDK%B3:N MRKRR4$"2TB9QYDW&XYG'"14X"D3%[[@N42PKH4,\;2'DAD])B/W96XP[^%D=.,?>7M+I :07XV%>$QNBGAU&_5?N M0?*K;?)VOF7KL@?3K_=K^_WSU\!N=I'>?GK-P45!*D5W?I?8 :8RX8"6A(7X MEC"Z4-1FI813MG;PQ *Q9%(A;1K'2/$M4CZYL.\\VU,-#Z="JKJVJ^!^%\WT MG<#&LP(I8ZW "79 %!1$:U#BSCCUY!I\%D*-/5\71F&FR-J?3'&74 ^FR$*J M!%1;QL<;* H8I%:.HEEN1RT+SP:UEMP8"269%*36L,EH#$,; V,/]H/[EFYQ MK]+>F8[MB8K6-((:T]$XQ_+WV1QWG_9EO*B@2ZD_5F8YHO9MI\"]@I2N:G^5 MM@*&V/UA=E(4;/V!T4QP<(L_N& 4D$T>RJ6B3Z::;978 * P6H+2-.XC/Q0I MYK#2FW9:I<.:)R>H^=_NLW=V+N MZ[?%D7VF1/BK_9!Q;JB:%%1IJEHO)PF M"8AGM["AUV1A'M-;_&9^ BFIF)ZWP1!W]A=(:,7?M;/N[48TLSK[LUV>/ZL+ M=B_VZ ]02P,$% @ :81>49>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'HH# !;&0 #P 'AL M+W=O)W)RMS!CO;B]2FQG3A?3ISSVT?8OD/$1 M\."N5 =[*54 =RX"?'&V7DHS;[K!N^A%M]'&8;7M@GCH_B6,=C:3)9S;LM9@ M0A='!ZH!-'XAESYC1F@89JM#F# 5NS !@\1&INL*CVWN%"\]JKJ[#H@;Q= = M2FQPHZH%3P=YAF6K9(57K]BI4,*4P-K@^NT[(R)(3D#RC4&RL7 19$% %O\1 M6LA)K;5P+VWDY-Q(/$U@0CHI2UMC0HH@]PG(_;20MU!"!&7F#-5C<+]L M0QI!'A"0!VDA3[S'GB=" =NZ1C'Z3W'^[E,)O)]X(.)H:Q73[ES\K.4C4C9# ML:DV6DES@(VRG9E?68J@T[K:6J,)YKH:2LDB?6RH5PIN%A8W XQ1%N+7J42O)- MNF1MZI!3,LD3VX3&+&),2B=Y8I^067LMFIR2"T\LE[]D;;:%ZRVUEH X)1>> M6"[OWYH58:QI3BYA$@N&'I<[,2;E&Y[8-S3F;HQ)&8/PQ,:A M,?=B3$HZ/+%T:,S]&),R$$]LH'@.?@Y!2+7^>E/:X8FU0^?S6#N8E':*Q-KY<]'PX; L*.L4R;^<$\;)J6'VC<(B?%$7W2#/*K*CC-_5H\C;+U=FX=K4OKBV M/KE79>UWI@BA_;#6YX6K,C]K6E?W;\Y-5V6A7W87VV;Y+;LXRVFZM-WK#+/? MOLY,CH_6_6=BM(&@5/V@- M0>OX01L(VL0/HA1E3!4D3;!6H#4AUZ3 :T*P28'8A&23 K,)T28%:A.R30K< M)H2;%,A-2#K$!O1KU9@=X\^=E6H#>CWJQ ;T:]68'>C'JS M KT9]68%>C/JS0KT9M2;%>C-J#HD!O0;U%@=XRN2Q1H+>@ MWJ) ;T&]18'>@GJ+ KT%]99WZNW#HW1^['FN\?QW4AWZ;]UX_+!\;D[8&7"V M< V]_P502P,$% @ :81>4:IG%&&8 0 "Q< !, !;0V]N=&5N=%]4 M>7!E&ULS9C-;L(P$(1?)^@)ML2$026[:A\/9U MPH_4BD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z\-X^,N;2@6KE$&VK"3JYM MK7QXM0MF5+I4"V)B-!JS5#>>&C_TK48\FSQ3KE:5CUXVX;,K=3.-+54NCIYV MA:W7-%;&5&6J?-AGZR;[X3+<.R2ALZMQ16G<(!3$[*1#N_.[P;[O;4W6EAE% M=YF5*FTU4=6A)G+*G,%42^KI*=Z*#?V8<; MIMV37^W?R?09ALJYU<:%B5FZW.XPDK9[:((065_V'_'H&*2O/A^UT\XH.],[ M7.^GMLMN'HYUR_5W_'W&1_T+Y!40=!36*! L0 ! M ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " !IA%Y1 M&YE0H.X K @ $0 @ &O 9&]C4')O<',O8V]R92YX M;6Q02P$"% ,4 " !IA%Y1F5R<(Q & "<)P $P @ ', M 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( &F$7E&(@H8%/@4 M ($5 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ :81>4<%2 M<]P. P (PH !@ ("!R!, 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ :81>43I>0',1"@ PD( !@ M ("!]"$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ :81>479'(H[6! /PL !@ ("!\$D 'AL M+W=O&UL4$L! A0#% @ :81>4:J&FH"/ P 2@D !D ("! M950 'AL+W=O&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% M @ :81>45R1T8A8!@ >0X !D ("!AVH 'AL+W=O&UL4$L! A0#% @ :81>48,)1#YY M! [@H !D ("!'8( 'AL+W=O&PO=V]R:W-H965TZ7 !X;"]W;W)K&UL4$L! A0#% @ :81>412N,64] P ,P@ !D M ("!OYP 'AL+W=O&PO=V]R M:W-H965TC !X;"]W;W)K&UL M4$L! A0#% @ :81>48,.8IS: @ NP@ !D ("!(Z< M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M:81>42GT:5*W @ 9@< !D ("!D[( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ :81>47@$Y >D!0 C1< !D M ("!N,< 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ :81>4?R?<2WP 0 R@, !D ("!F=4 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ :81> M46QEHH# !;&0 #P M @ %(X@ >&PO=V]R:V)O;VLN>&UL4$L! A0#% @ :81>49D^ MHH1\ 0 EA8 !H ( !_^4 'AL+U]R96QS+W=O4:IG%&&8 0 "Q< !, M ( !L^< %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& "T +0 R# &?.D end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 135 302 1 false 22 0 false 5 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.lexpharma.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets-Unaudited Sheet http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets-Unaudited Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets Parentheticals Sheet http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets Parentheticals Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited Sheet http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited Consolidated Statements of Comprehensive Loss-Unaudited Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals Sheet http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals Consolidated Statements of Comprehensive Loss Parentheticals Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited Sheet http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited Consolidated Statements of Stockholders' Equity/Deficit-Unaudited Statements 6 false false R7.htm 1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101101 - Disclosure - Summary of Significant Accounting Policies (Notes) Notes http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes Summary of Significant Accounting Policies (Notes) Notes 8 false false R9.htm 2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes) Notes http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes Recent Accounting Pronouncements Level 1 (Notes) Notes 9 false false R10.htm 2111103 - Disclosure - Asset Sale (Notes) Notes http://www.lexpharma.com/role/AssetSaleNotes Asset Sale (Notes) Notes 10 false false R11.htm 2113104 - Disclosure - Cash and Cash Equivalents and Investments Sheet http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments Cash and Cash Equivalents and Investments Notes 11 false false R12.htm 2117105 - Disclosure - Fair Value Measurements Sheet http://www.lexpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2120106 - Disclosure - Debt Obligations Sheet http://www.lexpharma.com/role/DebtObligations Debt Obligations Notes 13 false false R14.htm 2123107 - Disclosure - Commitments and Contingencies Sheet http://www.lexpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 2125108 - Disclosure - Collaboration and License Agreements Sheet http://www.lexpharma.com/role/CollaborationandLicenseAgreements Collaboration and License Agreements Notes 15 false false R16.htm 2128109 - Disclosure - Impairment Loss on Buildings Sheet http://www.lexpharma.com/role/ImpairmentLossonBuildings Impairment Loss on Buildings Notes 16 false false R17.htm 2132110 - Disclosure - Earnings Per Share Sheet http://www.lexpharma.com/role/EarningsPerShare Earnings Per Share Notes 17 false false R18.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes 18 false false R19.htm 2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables Summary of Significant Accounting Policies Equity Incentive Awards (Tables) Tables 19 false false R20.htm 2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables) Sheet http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables Cash and Cash Equivalents and Investments (Tables) Tables http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments 20 false false R21.htm 2318303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.lexpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.lexpharma.com/role/FairValueMeasurements 21 false false R22.htm 2333307 - Disclosure - Earnings Per Share (Tables) Sheet http://www.lexpharma.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.lexpharma.com/role/EarningsPerShare 22 false false R23.htm 2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails Summary of Significant Accounting Policies Inventory (Details) Details http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables 23 false false R24.htm 2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) Details 24 false false R25.htm 2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1 Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) Details 25 false false R26.htm 2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails Summary of Significant Accounting Policies Accrued Liabilities (Details) Details 26 false false R27.htm 2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details) Sheet http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails Summary of Significant Accounting Policies Intangible Assets (Details) Details 27 false false R28.htm 2412408 - Disclosure - Asset Sale (Details) Sheet http://www.lexpharma.com/role/AssetSaleDetails Asset Sale (Details) Details http://www.lexpharma.com/role/AssetSaleNotes 28 false false R29.htm 2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1) Sheet http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1 Cash and Cash Equivalents and Investments (Details 1) Details http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables 29 false false R30.htm 2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2) Sheet http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2 Cash and Cash Equivalents and Investments (Details 2) Details http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables 30 false false R31.htm 2419411 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.lexpharma.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.lexpharma.com/role/FairValueMeasurementsTables 31 false false R32.htm 2422412 - Disclosure - Debt Obligations (Details) Sheet http://www.lexpharma.com/role/DebtObligationsDetails Debt Obligations (Details) Details http://www.lexpharma.com/role/DebtObligations 32 false false R33.htm 2424413 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.lexpharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.lexpharma.com/role/CommitmentsandContingencies 33 false false R34.htm 2427414 - Disclosure - Collaboration and License Agreements (Details) Sheet http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails Collaboration and License Agreements (Details) Details http://www.lexpharma.com/role/CollaborationandLicenseAgreements 34 false false R35.htm 2430415 - Disclosure - Impairment Loss on Buildings (Details) Sheet http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails Impairment Loss on Buildings (Details) Details http://www.lexpharma.com/role/ImpairmentLossonBuildings 35 false false R36.htm 2434416 - Disclosure - Earnings Per Share (Details) Sheet http://www.lexpharma.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.lexpharma.com/role/EarningsPerShareTables 36 false false R9999.htm Uncategorized Items - lxrx-20200930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - lxrx-20200930.htm Cover 37 false false All Reports Book All Reports lxrx-20200930.htm exh11openmarketsaleagr.htm exh311certificationofp.htm exh312certificationofp.htm exh321certificationofp.htm exh51veopinion10-30x20.htm lxrx-20200930.xsd lxrx-20200930_cal.xml lxrx-20200930_def.xml lxrx-20200930_lab.xml lxrx-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lxrx-20200930.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 135, "dts": { "calculationLink": { "local": [ "lxrx-20200930_cal.xml" ] }, "definitionLink": { "local": [ "lxrx-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "lxrx-20200930.htm" ] }, "labelLink": { "local": [ "lxrx-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "lxrx-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "lxrx-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 342, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 49, "keyStandard": 253, "memberCustom": 3, "memberStandard": 19, "nsprefix": "lxrx", "nsuri": "http://www.lexpharma.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.lexpharma.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "lxrx:SaleOfNonFinancialAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111103 - Disclosure - Asset Sale (Notes)", "role": "http://www.lexpharma.com/role/AssetSaleNotes", "shortName": "Asset Sale (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "lxrx:SaleOfNonFinancialAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Cash and Cash Equivalents and Investments", "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments", "shortName": "Cash and Cash Equivalents and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Fair Value Measurements", "role": "http://www.lexpharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Debt Obligations", "role": "http://www.lexpharma.com/role/DebtObligations", "shortName": "Debt Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Commitments and Contingencies", "role": "http://www.lexpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125108 - Disclosure - Collaboration and License Agreements", "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements", "shortName": "Collaboration and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetImpairmentChargesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - Impairment Loss on Buildings", "role": "http://www.lexpharma.com/role/ImpairmentLossonBuildings", "shortName": "Impairment Loss on Buildings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetImpairmentChargesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132110 - Disclosure - Earnings Per Share", "role": "http://www.lexpharma.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables", "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited", "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "shortName": "Consolidated Balance Sheets-Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)", "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables", "shortName": "Cash and Cash Equivalents and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333307 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.lexpharma.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i47dc383a1189487da19aa61e7d8cdb1e_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails", "shortName": "Summary of Significant Accounting Policies Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i47dc383a1189487da19aa61e7d8cdb1e_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails", "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i6dd55aa47b494c508a8707104b290757_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i6dd55aa47b494c508a8707104b290757_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails", "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails", "shortName": "Summary of Significant Accounting Policies Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i806bb79355704a3d9f9e975c7764b751_I20170331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:GainOnSaleOfNonFinancialAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - Asset Sale (Details)", "role": "http://www.lexpharma.com/role/AssetSaleDetails", "shortName": "Asset Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:GainOnSaleOfNonFinancialAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i1258c23791be46e7aa4cc649d072022f_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)", "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1", "shortName": "Cash and Cash Equivalents and Investments (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i1258c23791be46e7aa4cc649d072022f_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals", "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets Parentheticals", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RealizedInvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)", "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2", "shortName": "Cash and Cash Equivalents and Investments (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RealizedInvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - Fair Value Measurements (Details 1)", "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1", "shortName": "Fair Value Measurements (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "if73dd8addd4542a29c4ec9debd3582d1_I20171218", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Debt Obligations (Details)", "role": "http://www.lexpharma.com/role/DebtObligationsDetails", "shortName": "Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "if73dd8addd4542a29c4ec9debd3582d1_I20171218", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "lxrx:Lxrx_Sanofiterminationcashpayment", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "lxrx:Lxrx_Sanofiterminationcashpayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "lxrx:Lxrx_Sanofiterminationcashpayment", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "lxrx:Lxrx_Sanofiterminationcashpayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427414 - Disclosure - Collaboration and License Agreements (Details)", "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails", "shortName": "Collaboration and License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "lxrx:SanofiRevenueRecognized", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "lxrx:SanofiRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:AssetSalePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Impairment Loss on Buildings (Details)", "role": "http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails", "shortName": "Impairment Loss on Buildings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:AssetSalePrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Earnings Per Share (Details)", "role": "http://www.lexpharma.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:Netproductrevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited", "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:Netproductrevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals", "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals", "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "if3ef5ec99dcc48139089e172def809d5_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited", "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)", "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes", "shortName": "Summary of Significant Accounting Policies (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)", "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes", "shortName": "Recent Accounting Pronouncements Level 1 (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i170f779ba4fd4cdb814e7d6c94490a0b_I20200908", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:LiabilitiesAssumedByTerSera", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - lxrx-20200930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - lxrx-20200930.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lxrx-20200930.htm", "contextRef": "i170f779ba4fd4cdb814e7d6c94490a0b_I20200908", "decimals": "-3", "first": true, "lang": "en-US", "name": "lxrx:LiabilitiesAssumedByTerSera", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "lxrx_AccruedCompensationAndBenefitsCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued compensation and benefits current - due within 1 year", "label": "Accrued compensation and benefits current", "terseLabel": "Accrued compensation and benefits current" } } }, "localname": "AccruedCompensationAndBenefitsCurrent", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_AccruedInterestOnConvertible": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "accrued interest on convertible", "label": "accrued interest on convertible", "terseLabel": "accrued interest on convertible" } } }, "localname": "AccruedInterestOnConvertible", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_AccruedLiabilitiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accrued liabilities", "label": "accrued liabilities [Axis]", "terseLabel": "Accrued Liabilities [Axis]" } } }, "localname": "AccruedLiabilitiesAxis", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "lxrx_AccruedLiabilitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities", "label": "Accrued Liabilities [Domain]", "terseLabel": "Accrued Liabilities [Domain]" } } }, "localname": "AccruedLiabilitiesDomain", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "lxrx_AccruedLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities", "label": "Accrued Liabilities [Line Items]", "terseLabel": "Accrued Liabilities [Line Items]" } } }, "localname": "AccruedLiabilitiesLineItems", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "lxrx_AccruedLiabilitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accrued liabilities [Table]", "label": "accrued liabilities [Table]", "terseLabel": "Accrued Liabilities [Table]" } } }, "localname": "AccruedLiabilitiesTable", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "lxrx_AccruedResearchAndDevelopmentServicesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued research and development services current", "label": "Accrued research and development services current", "terseLabel": "Accrued research and development services current" } } }, "localname": "AccruedResearchAndDevelopmentServicesCurrent", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_AssetSalePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "asset sale price", "label": "asset sale price", "terseLabel": "asset sale price" } } }, "localname": "AssetSalePrice", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_BioPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioPharma", "label": "BioPharma [Member]", "terseLabel": "BioPharma [Member]" } } }, "localname": "BioPharmaMember", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash and Cash Equivalents and Investments [Abstract]", "label": "Cash and Cash Equivalents and Investments [Abstract]", "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]" } } }, "localname": "CashAndCashEquivalentsAndInvestmentsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_CollaborationAndLicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and License Agreements [Abstract]", "label": "Collaboration and License Agreements [Abstract]", "terseLabel": "Collaboration and License Agreements [Abstract]" } } }, "localname": "CollaborationAndLicenseAgreementsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_ConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated Balance Sheets [Abstract]", "label": "Consolidated Balance Sheets [Abstract]", "terseLabel": "Consolidated Balance Sheets [Abstract]" } } }, "localname": "ConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated Statements of Cash Flows [Abstract]", "label": "Consolidated Statements of Cash Flows [Abstract]", "terseLabel": "Consolidated Statements of Cash Flows [Abstract]" } } }, "localname": "ConsolidatedStatementsOfCashFlowsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_ConsolidatedStatementsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated Statements of Operations [Abstract]", "label": "Consolidated Statements of Operations [Abstract]", "terseLabel": "Consolidated Statements of Operations [Abstract]" } } }, "localname": "ConsolidatedStatementsOfOperationsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]", "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]", "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]" } } }, "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement", "label": "Conv Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage" } } }, "localname": "ConvDebtInstrumentInterestRateStatedPercentage", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "percentItemType" }, "lxrx_ConvertibleDebtExchange": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange", "label": "Convertible debt exchange", "terseLabel": "Convertible debt exchange" } } }, "localname": "ConvertibleDebtExchange", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_ConvertibleDebtExchangeRemainingNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange Remaining Notes", "label": "Convertible debt exchange Remaining Notes", "terseLabel": "Convertible debt exchange Remaining Notes" } } }, "localname": "ConvertibleDebtExchangeRemainingNotes", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange- September cash portion", "label": "Convertible debt exchange- September cash portion", "terseLabel": "Convertible debt exchange- September cash portion" } } }, "localname": "ConvertibleDebtExchangeSeptemberCashPortion", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange - September principal amount", "label": "Convertible debt exchange - September principal amount", "terseLabel": "Convertible debt exchange - September principal amount" } } }, "localname": "ConvertibleDebtExchangeSeptemberPrincipalAmount", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange - September share payment", "label": "Convertible debt exchange - September share payment", "terseLabel": "Convertible debt exchange - September share payment" } } }, "localname": "ConvertibleDebtExchangeSeptemberSharePayment", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "sharesItemType" }, "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Convertible debt exchange - Total Principal Amount", "label": "Convertible debt exchange - Total Principal Amount", "terseLabel": "Convertible debt exchange - Total Principal Amount" } } }, "localname": "ConvertibleDebtExchangeTotalPrincipalAmount", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_DebtObligationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Obligations [Abstract]", "label": "Debt Obligations [Abstract]", "terseLabel": "Debt Obligations [Abstract]" } } }, "localname": "DebtObligationsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_FairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Measurements [Abstract]", "label": "Fair Value Measurements [Abstract]", "terseLabel": "Fair Value Measurements [Abstract]" } } }, "localname": "FairValueMeasurementsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_FutureConvertibleDebtExchange": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "future convertible debt exchange", "label": "future convertible debt exchange", "terseLabel": "future convertible debt exchange" } } }, "localname": "FutureConvertibleDebtExchange", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_FutureConvertibleDebtExchangeShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Future Convertible debt exchange shares", "label": "Future Convertible debt exchange shares", "terseLabel": "Future Convertible debt exchange shares" } } }, "localname": "FutureConvertibleDebtExchangeShares", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "sharesItemType" }, "lxrx_GainOnSaleOfNonFinancialAssets": { "auth_ref": [], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain on sale of non-financial assets", "label": "Gain on sale of non-financial assets", "negatedTerseLabel": "Gain on sale of non-financial assets", "terseLabel": "Gain on sale of non-financial assets" } } }, "localname": "GainOnSaleOfNonFinancialAssets", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_InventoryAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory [Abstract]", "label": "Inventory [Abstract]", "terseLabel": "Inventory [Abstract]" } } }, "localname": "InventoryAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.", "label": "Ipsen Maximum Regulatory And Commercial Milestones", "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones" } } }, "localname": "IpsenMaximumRegulatoryAndCommercialMilestones", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenMaximumSalesMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.", "label": "Ipsen Maximum Sales Milestones", "terseLabel": "Ipsen Maximum Sales Milestones" } } }, "localname": "IpsenMaximumSalesMilestones", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.", "label": "Ipsen Milestone Payment", "terseLabel": "Ipsen Milestone Payment" } } }, "localname": "IpsenMilestonePayment", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenMilestonePaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.", "label": "Ipsen Milestone Payment Received", "terseLabel": "Ipsen Milestone Payment Received" } } }, "localname": "IpsenMilestonePaymentReceived", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.", "label": "Ipsen Revenue Allocated to Committee Deliverable", "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable" } } }, "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.", "label": "Ipsen Revenue Allocated to Development Deliverable", "terseLabel": "Ipsen Revenue Allocated to Development Deliverable" } } }, "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.", "label": "Ipsen Revenue Allocated to License Deliverable", "terseLabel": "Ipsen Revenue Allocated to License Deliverable" } } }, "localname": "IpsenRevenueAllocatedtoLicenseDeliverable", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.", "label": "Ipsen Revenue Recognized", "terseLabel": "Ipsen Revenue Recognized" } } }, "localname": "IpsenRevenueRecognized", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenRoyaltyIncome_LXRX": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.", "label": "Ipsen Royalty Income_LXRX", "terseLabel": "Ipsen Royalty Income_LXRX" } } }, "localname": "IpsenRoyaltyIncome_LXRX", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenTotalPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.", "label": "Ipsen Total Payments", "terseLabel": "Ipsen Total Payments" } } }, "localname": "IpsenTotalPayments", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_IpsenTotalUpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.", "label": "Ipsen Total Upfront Payments", "terseLabel": "Ipsen Total Upfront Payments" } } }, "localname": "IpsenTotalUpfrontPayments", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_LiabilitiesAssumedByTerSera": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Liabilities assumed by TerSera", "label": "Liabilities assumed by TerSera", "terseLabel": "Liabilities assumed by TerSera" } } }, "localname": "LiabilitiesAssumedByTerSera", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_Lxrx_Sanofiterminationcashpayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance", "label": "lxrx_Sanofi termination cash payment", "terseLabel": "Sanofi termination cash payment" } } }, "localname": "Lxrx_Sanofiterminationcashpayment", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails", "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_Lxrx_sanofiInitialCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "lxrx_sanofi initial cash payment", "label": "lxrx_sanofi initial cash payment", "terseLabel": "lxrx_sanofi initial cash payment" } } }, "localname": "Lxrx_sanofiInitialCashPayment", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_MortgageDebtBalloonPayment_LXRX": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.", "label": "Mortgage Debt Balloon Payment_LXRX", "terseLabel": "Mortgage Debt Balloon Payment_LXRX" } } }, "localname": "MortgageDebtBalloonPayment_LXRX", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_MortgageDebtInstrument_Revere_LXRX": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral", "label": "Mortgage Debt Instrument_Revere_LXRX", "terseLabel": "Mortgage Debt Instrument_Revere_LXRX" } } }, "localname": "MortgageDebtInstrument_Revere_LXRX", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%", "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX", "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX" } } }, "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "percentItemType" }, "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%", "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX", "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX" } } }, "localname": "MortgageDebtInterestRate_Base_Revere_LXRX", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "percentItemType" }, "lxrx_Netproductrevenue": { "auth_ref": [], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.", "label": "Net product revenue", "terseLabel": "Net product revenue" } } }, "localname": "Netproductrevenue", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_PrincipalAmountOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "principal amount of convertible notes", "label": "principal amount of convertible notes", "terseLabel": "principal amount of convertible notes" } } }, "localname": "PrincipalAmountOfConvertibleNotes", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_RDSeveranceCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "R&D severance costs", "label": "R&D severance costs [Member]", "terseLabel": "R&D severance costs [Member]" } } }, "localname": "RDSeveranceCostsMember", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "lxrx_RecentAccountingPronouncementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recent Accounting Pronouncements [Abstract]", "label": "Recent Accounting Pronouncements [Abstract]", "terseLabel": "Recent Accounting Pronouncements [Abstract]" } } }, "localname": "RecentAccountingPronouncementsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_SGASeveranceCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SG&A severance costs", "label": "SG&A severance costs [Member]", "terseLabel": "SG&A severance costs [Member]" } } }, "localname": "SGASeveranceCostsMember", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "lxrx_SaleOfNonFinancialAssetsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of Non-Financial Assets", "label": "Sale of Non-Financial Assets [Text Block]", "terseLabel": "Sale of Non-Financial Assets" } } }, "localname": "SaleOfNonFinancialAssetsTextBlock", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleNotes" ], "xbrltype": "textBlockItemType" }, "lxrx_SanofiRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.", "label": "Sanofi Revenue Recognized", "terseLabel": "Sanofi Revenue Recognized" } } }, "localname": "SanofiRevenueRecognized", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]" } } }, "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_Sellinggeneralandadministrativeexpenses": { "auth_ref": [], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.", "label": "Selling, general and administrative expenses", "terseLabel": "Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively" } } }, "localname": "Sellinggeneralandadministrativeexpenses", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "durationItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "durationItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "percentItemType" }, "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock-based compensation expense included in research and development expense.", "label": "Stock-based compensation expense associated with research and development expense", "terseLabel": "Stock-based compensation expense associated with research and development expense" } } }, "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock-based compensation expense associated with selling, general and administrative expense", "label": "Stock-based compensation expense associated with selling, general and administrative expense", "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense" } } }, "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of Significant Accounting Policies [Abstract]", "label": "Summary of Significant Accounting Policies [Abstract]", "terseLabel": "Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.lexpharma.com/20200930", "xbrltype": "stringItemType" }, "lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "TerSera Maximum Development, Regulatory and Commercial Milestones", "label": "TerSera Maximum Development, Regulatory and Commercial Milestones", "terseLabel": "TerSera Maximum Development, Regulatory and Commercial Milestones" } } }, "localname": "TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "monetaryItemType" }, "lxrx_XermeloPretaxNetLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Xermelo Pretax Net Loss", "label": "Xermelo Pretax Net Loss", "terseLabel": "Xermelo Pretax Net Loss" } } }, "localname": "XermeloPretaxNetLoss", "nsuri": "http://www.lexpharma.com/20200930", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "monetaryItemType" }, "srt_RangeAxis": { "auth_ref": [ "r216", "r225", "r227", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r342", "r343" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r216", "r225", "r227", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r342", "r343" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r196", "r226", "r298" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r20", "r164", "r165" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r318", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r29", "r186" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation and amortization, property and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r53", "r54", "r55", "r331", "r348", "r349" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r55", "r56", "r97", "r98", "r99", "r272", "r344", "r345" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r254" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r97", "r98", "r99", "r251", "r252", "r253" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r230", "r255", "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r84", "r294" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r84", "r182", "r184" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r84", "r185" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset Impairment Charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentChargesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.", "label": "Asset Impairment Charges [Text Block]", "terseLabel": "Asset Impairment Charges" } } }, "localname": "AssetImpairmentChargesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ImpairmentLossonBuildings" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetRetirementObligationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asset Retirement Obligation Disclosure [Abstract]" } } }, "localname": "AssetRetirementObligationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r150", "r153", "r159", "r174", "r269", "r273", "r283", "r312", "r330" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r50", "r93", "r174", "r269", "r273", "r283" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Short-term Investments" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r173" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r231", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r231", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r28", "r86" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash and Cash Equivalents Disclosure" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r87", "r89" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r92", "r93", "r112", "r116", "r119", "r123", "r127", "r136", "r137", "r138", "r174", "r283" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r264", "r265", "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangement Disclosure" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CollaborationandLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r195", "r319", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r192", "r193", "r194", "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r97", "r98" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r58", "r60", "r61", "r66", "r322", "r338" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r89", "r271" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r217", "r224", "r350" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r68", "r309" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Goods and Service [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Disclosure" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r15", "r16", "r313", "r314", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r37", "r205", "r206", "r208" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt Instrument, Convertible, Conversion Ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r293", "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r38", "r95", "r205", "r207", "r208", "r209", "r292", "r293", "r295", "r327" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r258", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Income Tax Benefit" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt Issuance Costs, Gross" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r94", "r258", "r261", "r262", "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r84", "r149" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r67", "r102", "r103", "r104", "r105", "r106", "r110", "r112", "r123", "r126", "r127", "r131", "r132", "r323", "r339" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per common share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r67", "r102", "r103", "r104", "r105", "r106", "r112", "r123", "r126", "r127", "r131", "r132", "r323", "r339" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted", "verboseLabel": "Net income (loss) per common share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r89", "r128", "r129" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128", "r129", "r130", "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r97", "r98", "r99", "r101", "r107", "r109", "r135", "r175", "r204", "r210", "r251", "r252", "r253", "r259", "r260", "r284", "r285", "r286", "r287", "r288", "r289", "r344", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1", "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r277", "r281", "r282" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r277", "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r278", "r299", "r300", "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r217", "r218", "r223", "r224", "r278", "r299" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r217", "r218", "r223", "r224", "r278", "r300" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r278", "r301" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value, Measurement Inputs, Disclosure" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r299", "r300", "r301" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r84", "r200", "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r179", "r180", "r311" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r84", "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "terseLabel": "Impairment of Real Estate" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r64", "r150", "r152", "r155", "r158", "r160", "r310", "r320", "r325", "r340" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Net Income (Loss) before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Decrease in accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "(Increase) decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Decrease in deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "(Increase) decrease in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Decrease in other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r117", "r118", "r127" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r113", "r114", "r115", "r127" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r181", "r183" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Intangible Assets, Net (Including Goodwill)" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r62", "r148", "r291", "r294", "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r79", "r81", "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory, Finished Goods, Gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r47" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r48", "r89", "r134", "r176", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Inventory, Raw Materials, Gross" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Inventory, Work in Process, Gross" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investment [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Total Cash and Cash Equivalents and Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/FairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]", "terseLabel": "Total Cash and Cash Equivalents and Investments" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r93", "r154", "r174", "r270", "r273", "r274", "r283" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r93", "r174", "r283", "r315", "r333" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r93", "r174", "r270", "r273", "r274", "r283" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt, net of deferred issuance costs" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of deferred issuance costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r38", "r198" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r80", "r82", "r85" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r57", "r59", "r65", "r85", "r93", "r100", "r102", "r103", "r104", "r105", "r108", "r109", "r121", "r150", "r152", "r155", "r158", "r160", "r174", "r283", "r321", "r337" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r152", "r155", "r158", "r160" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r34" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r51", "r53" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Debt Issuance Cost" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r74" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r231", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r72" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from Sale of Productive Assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r187", "r334" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "terseLabel": "Realized Investment Gains (Losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of debt borrowings, net of fees" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r257", "r367" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r89", "r257" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r210", "r254", "r332", "r347", "r349" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r97", "r98", "r99", "r101", "r107", "r109", "r175", "r251", "r252", "r253", "r259", "r260", "r344", "r346" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r151", "r156", "r157", "r161", "r162", "r163", "r213", "r214", "r309" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaborative agreements" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r90", "r91" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r63", "r93", "r146", "r147", "r151", "r156", "r157", "r161", "r162", "r163", "r174", "r283", "r325" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyIncomeNonoperating": { "auth_ref": [ "r69" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Income, Nonoperating", "terseLabel": "Royalties and other revenue" } } }, "localname": "RoyaltyIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of cash and cash equivalents and investments", "verboseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1", "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r231", "r250" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r234", "r246", "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r84", "r189", "r190", "r191" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance Costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r236", "r250" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r229", "r232" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r89", "r231", "r233" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r14", "r316", "r317", "r329" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r363", "r364", "r365", "r366" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Total Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r92", "r93", "r112", "r116", "r119", "r123", "r127", "r136", "r137", "r138", "r174", "r204", "r283" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r97", "r98", "r99", "r101", "r107", "r109", "r135", "r175", "r204", "r210", "r251", "r252", "r253", "r259", "r260", "r284", "r285", "r286", "r287", "r288", "r289", "r344", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r97", "r98", "r99", "r135", "r309" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r204", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r204", "r210" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock under Equity Incentive Plans, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r24", "r25", "r93", "r171", "r174", "r283" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholder's equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r93", "r97", "r98", "r99", "r101", "r107", "r174", "r175", "r210", "r251", "r252", "r253", "r259", "r260", "r267", "r268", "r275", "r283", "r284", "r285", "r289", "r345", "r346" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, value", "periodStartLabel": "Balance, value" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r290", "r297" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r290", "r297" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r290", "r297" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r166", "r167", "r168", "r169", "r170", "r172" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]", "terseLabel": "Trading Activity, by Type [Axis]" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).", "label": "Trading Activity, by Type [Domain]", "terseLabel": "Trading Activity, by Type [Domain]" } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r211" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r211" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r211", "r212" ], "calculation": { "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 793 and 407 shares, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r204", "r210", "r211" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/AssetSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r217", "r224", "r326" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized Debt Issuance Expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/DebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": { "auth_ref": [ "r120", "r122", "r124", "r125" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted", "terseLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1", "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r127" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r110", "r127" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Shares used in computing net loss per common share, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.lexpharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r368": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r371": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r372": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r373": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" } }, "version": "2.1" } ZIP 57 0001062822-20-000067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001062822-20-000067-xbrl.zip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